PRODUCT MONOGRAPH

INCLUDING PATIENT MEDICATION INFORMATION

PrM-DAPAGLIFLOZIN

Dapagliflozin Tablets Tablets, 5 mg and 10 mg, Oral

ATC Code: A10BK01

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Mantra Pharma Inc. 9150 Leduc Blvd., Suite 201 Brossard, Quebec J4Y 0E3 Date of Initial Authorization: FEB 08, 2023

Submission Control Number: 264257

RECENT MAJOR LABEL CHANGES

N/A

TABLE OF CONTENTS

Section	s or sub	sections that are not applicable at the time of authorization are not listed.
RECEN	т мајс	DR LABEL CHANGES2
TABLE	OF COM	NTENTS
PART I	HEALT	H PROFESSIONAL INFORMATION4
1	INDICA	ATIONS4
	1.1	Pediatrics
	1.2	Geriatrics
2	CONTR	AINDICATIONS4
3	SERIO	US WARNINGS AND PRECAUTIONS BOX5
4	DOSAG	GE AND ADMINISTRATION
	4.1	Dosing Considerations
	4.2	Recommended Dose and Dosage Adjustment5
	4.5	Missed Dose
5	OVERD	OOSAGE6
6	DOSAG	GE FORMS, STRENGTHS, COMPOSITION AND PACKAGING7
7	WARN	IINGS AND PRECAUTIONS7
	7.1	Special Populations
	7.1.1	Pregnant Women 11
	7.1.2	Breast-feeding
	7.1.3	Pediatrics11
	7.1.4	Geriatrics
8	ADVE	RSE REACTIONS
	8.1	Adverse Reaction Overview12
	8.2	Clinical Trial Adverse Reactions12
	8.3	Less Common Clinical Trial Adverse Reactions
	8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

	8.5	Post-Market Adverse Reactions
9	DRUG	INTERACTIONS22
	9.2	Drug Interactions Overview
	9.3	Drug-Behavioural Interactions
	9.4	Drug-Drug Interactions
	9.5	Drug-Food Interactions
	9.6	Drug-Herb Interactions
	9.7	Drug-Laboratory Test Interactions
10	CLINIC	AL PHARMACOLOGY26
	10.1	Mechanism of Action
	10.2	Pharmacodynamics
	10.3	Pharmacokinetics
11	STORA	GE, STABILITY AND DISPOSAL
12	SPECIA	AL HANDLING INSTRUCTIONS
PART I	I: SCIEN	ITIFIC INFORMATION
13	PHARM	ACEUTICAL INFORMATION
14	CLINIC	AL TRIALS
	14.1	Trial Design and Study Demographics
	14.2	Study Results
	14.3	Comparative Bioavailability Studies
15	MICRO	9BIOLOGY
16	NON-C	LINICAL TOXICOLOGY
17	SUPPO	RTING PRODUCT MONOGRAPHS46
PATIEN	NT MED	ICATION INFORMATION47

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Type 2 Diabetes Mellitus (T2DM)

Monotherapy: M-DAPAGLIFLOZIN (dapagliflozin tablets) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance.

Add-on combination: M-DAPAGLIFLOZIN is indicated in adult patients with T2DM to improve glycemic control in combination with

- metformin
- a sulfonylurea
- metformin and a sulfonylurea
- sitagliptin (alone or with metformin)
- insulin (alone or with metformin)

when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control.

1.1 Pediatrics

Pediatrics (<18 years of age): Safety and efficacy of dapagliflozin have not been established in patients under 18 years of age; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Type 2 Diabetes Mellitus (T2DM)

Geriatrics (≥65 years of age): M-DAPAGLIFLOZIN should be used with caution in this population as a higher proportion of patients ≥65 years of age treated with dapagliflozin had adverse reactions related to volume depletion and renal impairment or failure, compared to patients treated with placebo. See 7.1.4 Geriatrics and 8 ADVERSE REACTIONS.

2 CONTRAINDICATIONS

- M-DAPAGLIFLOZIN is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
- M-DAPAGLIFLOZIN is contraindicated in patients with an eGFR less than 30 mL/min/1.73m², end-stage renal disease (ESRD), or patients on dialysis (see 7 WARNINGS AND PRECAUTIONS, Renal).

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

Diabetic Ketoacidosis in Patients with Diabetes

- Clinical trial and post-market cases of diabetic ketoacidosis (DKA), a serious life-threatening condition requiring urgent hospitalization, have been reported in patients with T2DM treated with dapagliflozin and other sodium-glucose co-transporter 2 (SGLT2) inhibitors. A number of these cases have been atypical with blood glucose values below 13.9 mmol/L (250 mg/dL). Some cases of DKA have been fatal. See 8 ADVERSE REACTIONS.
- Patients should be assessed for DKA immediately if non-specific symptoms such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, anorexia, excessive thirst and unusual fatigue or sleepiness occur, regardless of blood glucose level. If DKA is suspected or diagnosed, M-DAPAGLIFLOZIN should be **discontinued immediately**.
- M-DAPAGLIFLOZIN should not be used for the treatment of DKA or in patients with a history of DKA.
- M-DAPAGLIFLOZIN is not indicated, and should not be used, in patients with type 1 diabetes.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- M-DAPAGLIFLOZIN may be taken at any time of the day with or without food.
- Assess renal function prior to initiation of M-DAPAGLIFLOZIN therapy and regularly thereafter. See 7 WARNINGS AND PRECAUTIONS.
- Assess volume status and, if necessary, correct volume depletion prior to initiation of M-DAPAGLIFLOZIN therapy. See 7 WARNINGS AND PRECAUTIONS.
- Concomitant use with insulin or an insulin secretagogue (e.g., sulfonylurea): When M-DAPAGLIFLOZIN is used as add-on therapy with insulin or an insulin secretagogue (e.g., sulfonylurea), a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. See 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS.

4.2 Recommended Dose and Dosage Adjustment

Type 2 Diabetes Mellitus (T2DM)

To improve glycemic control, the recommended starting dose of M-DAPAGLIFLOZIN is 5 mg taken orally once daily. In patients tolerating M-DAPAGLIFLOZIN 5 mg once daily and who require additional glycemic control, the dose can be increased to 10 mg daily.

Considerations for Special Populations

Renal impairment:

The glycemic efficacy of dapagliflozin is dependent on renal function and declines with decreasing renal function. Renal function should be assessed prior to initiation of M-DAPAGLIFLOZIN therapy and periodically thereafter, with more intensive monitoring of glycemic and renal biomarkers, and signs and symptoms of renal dysfunction in patients whose eGFR decreases <60 mL/min/1.73m².

No dosage adjustment for M-DAPAGLIFOZIN is required in T2DM patients, who are being treated for glycemic control, with mild to moderate (CKD 3A) renal impairment (eGFR ≥45 mL/min/1.73m²).

M-DAPAGLIFOZIN is not recommended for use in patients with T2DM, being treated for glycemic control, with an eGFR persistently <45 mL/min/1.73m², severe renal impairment, ESRD, or patients on dialysis as the glycemic efficacy of dapagliflozin is dependent on renal function (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS).

M-DAPAGLIFLOZIN is contraindicated in patients with an eGFR less than 30 mL/min/1.73m², end-stage renal disease (ESRD), or patients on dialysis (see 2 CONTRAINDICATIONS).

Hepatic impairment: No dosage adjustment for M-DAPAGLIFLOZIN is required for patients with mild or moderate hepatic impairment. Dapagliflozin exposure is increased in patients with severe hepatic impairment. See 10 CLINICAL PHARMACOLOGY. Therefore, M-DAPAGLIFLOZIN is not recommended for use in this population.

Pediatrics (<18 years of age): Safety and effectiveness of dapagliflozin in pediatric and adolescent patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

Geriatrics (≥65 years of age): No dosage adjustment for M-DAPAGLIFLOZIN is required based on age; however renal function and risk of volume depletion should be taken into account. See 7.1.4 Geriatrics.

4.5 Missed Dose

If a dose of M-DAPAGLIFLOZIN is missed, it should be taken as soon as the patient remembers. A double dose of M-DAPAGLIFLOZIN should not be taken on the same day.

5 OVERDOSAGE

It is reasonable to employ supportive measures, as dictated by the patient's clinical status. The removal of dapagliflozin by hemodialysis has not been studied.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Oral	Tablets 5 mg, 10 mg	Anhydrous lactose, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, iron oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, partially hydrolyzed polyvinyl alcohol, polyethylene glycol, talc and titanium dioxide.

Table 1 - Dosage Forms, Strengths, Composition and Packaging

M-DAPAGLIFLOZIN is available as a film-coated tablet for oral administration containing 5 mg or 10 mg dapagliflozin.

M-DAPAGLIFLOZIN 5 mg are yellow, biconvex, round shaped tablets debossed with "L644" on one side and plain on other side.

M-DAPAGLIFLOZIN 10 mg are yellow, biconvex, diamond shaped tablets debossed with "L645" on one side and plain on other side.

The 5 mg and 10 mg tablets are provided in bottles of 100 tablets, as well as in blister cartons containing 30 tablets (3 blister sleeves of 10 tablets).

7 WARNINGS AND PRECAUTIONS

Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.

General

Cardiovascular

Use in patients at risk for volume depletion, hypotension and/or electrolyte imbalances: Due to its mechanism of action, dapagliflozin causes osmotic diuresis that may be associated with decreases in blood pressure, which may be more pronounced in patients with high blood glucose concentrations.

M-DAPAGLIFLOZIN is not recommended for use in patients who are volume depleted.

Caution should be exercised in patients for whom a dapagliflozin induced drop in blood pressure could pose a risk, such as elderly patients, patients with low systolic blood pressure or moderate renal impairment, or in case of intercurrent conditions that may lead to volume depletion (such as gastrointestinal illness).

Careful monitoring of volume status is recommended. Temporary interruption of M-DAPAGLIFLOZIN may be considered for patients who develop volume depletion until the depletion is corrected. See 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests, and 8 ADVERSE REACTIONS.

Driving and Operating Machinery

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be advised to take precautions when driving or operating a vehicle or potentially dangerous machinery due to the elevated risk of adverse reactions related to reduced intravascular volume, such as postural dizziness, and to the risk of hypoglycemia when M-DAPAGLIFLOZIN is used as add-on therapy with insulin or an insulin secretagogue.

Endocrine and Metabolism

Diabetic ketoacidosis (DKA) in patients with diabetes: Clinical trial and post-market cases of DKA, a serious life-threatening condition requiring urgent hospitalization, have been reported in patients with T2DM treated with dapagliflozin and other SGLT2 inhibitors. In a number of reported cases, the presentation of the condition was atypical with only moderately increased blood glucose values below 13.9 mmol/L (250 mg/dL). Some cases of DKA have been fatal. See 8 ADVERSE REACTIONS.

M-DAPAGLIFLOZIN is not indicated, and should not be used, in patients with type 1 diabetes. The diagnosis of T2DM should therefore be confirmed before initiating M-DAPAGLIFLOZIN as a treatment to improve glycemic control.

DKA must be considered in the event of non-specific symptoms such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, anorexia, excessive thirst, and unusual fatigue or sleepiness. If DKA is suspected, regardless of blood glucose level, patients should discontinue M-DAPAGLIFLOZIN treatment and be assessed for DKA immediately.

Interruption of treatment with M-DAPAGLIFLOZIN should be considered in T2DM patients who are hospitalized for major surgical procedures, serious infections or acute serious medical illness.

Conditions that can precipitate DKA while taking M-DAPAGLIFLOZIN include a very low carbohydrate diet (as the combination may further increase ketone body production), dehydration, high alcohol consumption and a low beta-cell function reserve. These patients should be monitored closely. Caution should also be taken when reducing the insulin dose in patients requiring insulin. See 4 DOSAGE AND ADMINISTRATION.

Use with medications known to cause hypoglycemia: Insulin and insulin secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a lower dose of insulin or the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with M-DAPAGLIFLOZIN. See 4 DOSAGE AND ADMINISTRATION and 8 ADVERSE REACTIONS.

Increases in Low-Density Lipoprotein (LDL-C): Dose-related increases in LDL-C are seen with dapagliflozin treatment. See 8 ADVERSE REACTIONS. LDL-C levels should be monitored.

Genitourinary

Genital mycotic infections: Patients, particularly those with a history of genital mycotic infections, should be advised that M-DAPAGLIFLOZIN increases the risk of genital mycotic infections. See 8 ADVERSE REACTIONS.

Urinary tract infections (including urosepsis and pyelonephritis): Treatment with M-DAPAGLIFLOZIN increases the risk for urinary tract infections. See 8 ADVERSE REACTIONS.

There have been post-marketing reports of serious urinary tract infections, including urosepsis and pyelonephritis, requiring hospitalization in patients treated with dapagliflozin. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated.

Necrotizing fasciitis of the perineum (Fournier's gangrene): Post-marketing cases of necrotizing fasciitis of perineum (Fournier's gangrene), a rare but serious and potentially life-threatening necrotizing infection requiring urgent surgical intervention, have been reported in female and male patients with diabetes mellitus receiving SGLT2 inhibitors, including dapagliflozin. Serious outcomes have included hospitalization, multiple surgeries, and death. See 8.5 Post-Market Adverse Reactions.

Patients treated with M-DAPAGLIFLOZIN who present with pain or tenderness, erythema, or swelling in the genital or perineal area, with or without fever or malaise, should be evaluated for necrotizing fasciitis. If suspected, M-DAPAGLIFLOZIN should be discontinued and prompt treatment should be instituted (including broad-spectrum antibiotics and surgical debridement if necessary).

Hematologic

Elevated hemoglobin and hematocrit: Mean hemoglobin and hematocrit increased in patients administered dapagliflozin, as did the number of patients with abnormally elevated values for hemoglobin/hematocrit. See 8 ADVERSE REACTIONS.

M-DAPAGLIFLOZIN should be used with caution in patients with an elevated hematocrit.

Hepatic/Biliary/Pancreatic

Elevations in hepatic transaminases have been reported in dapagliflozin treated patients in clinical trials; however, a causal relationship with dapagliflozin has not been established. dapagliflozin exposure is increased in patients with severe hepatic impairment. Use of M-DAPAGLIFLOZIN is not recommended in patients with severe hepatic impairment. See 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY.

Monitoring and Laboratory Tests

Blood glucose and HbA1c: Response to dapagliflozin treatment in T2DM patients should be monitored by periodic measurements of blood glucose and HbA1c levels.

Due to its mechanism of action, patients taking M-DAPAGLIFLOZIN will test positive for glucose in their urine. See 9.7 Drug-Laboratory Test Interactions.

Renal function: Renal function should be assessed prior to initiation of M-DAPAGLIFLOZIN and regularly thereafter (see 4.2 Recommended Dose and Dosage Adjustment, Renal Impairment, and 7 WARNINGS AND PRECAUTIONS, Renal). M-DAPAGLIFLOZIN is not recommended for use in patients with T2DM, being treated for glycemic control, with an eGFR persistently <45 mL/min/1.73m², severe renal impairment, ESRD, or patients on dialysis as the glycemic efficacy of dapagliflozin is dependent on renal function (see 4.2 Recommended Dose and Dosage Adjustment, Renal Impairment, 8 ADVERSE REACTIONS, and 14 CLINICAL TRIALS). M-DAPAGLIFLOZIN is contraindicated in patients with an eGFR less than 30 mL/min/1.73m², ESRD, or patients on dialysis (see 2 CONTRAINDICATIONS).

Reduced intravascular volume: M-DAPAGLIFLOZIN is not recommended for use in patients who are volume depleted. Before initiating M-DAPAGLIFLOZIN, assess volume status, particularly in patients at risk as well as in case of intercurrent conditions that may lead to fluid loss (such as a gastrointestinal illness) for patients already taking M-DAPAGLIFLOZIN.

In these patients, careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests, including hematocrit, serum electrolytes and renal function tests) is recommended. If volume depletion develops, temporary interruption of treatment with M-DAPAGLIFLOZIN may be considered until fluid loss is corrected.

LDL-cholesterol: LDL-C levels should be measured at baseline and at regular intervals during treatment with M-DAPAGLIFLOZIN due to dose-dependent increases in LDL-C seen with therapy.

Renal

Initiation of M-DAPAGLIFLOZIN may transiently increase serum creatinine and decreases eGFR in a dose dependent fashion. In clinical trials, renal function abnormalities have occurred after initiating dapagliflozin.

Type 2 Diabetes Mellitus (T2DM)

Post-marketing cases of acute kidney injury, including acute renal failure, shortly after the initiation of dapagliflozin treatment have been reported in T2DM patients (see 8.5 Post-Market Adverse Reactions). Patients with hypovolemia may be more susceptible to these changes (see 8 ADVERSE REACTIONS).

Renal function should be assessed prior to initiation of M-DAPAGLIFLOZIN and regularly thereafter, with more frequent monitoring in patients whose eGFR decreases to <60 mL/min/1.73m².

M-DAPAGLIFLOZIN is not recommended for use in patients with T2DM, being treated for glycemic control, with an eGFR persistently <45 mL/min/1.73m², severe renal impairment, ESRD, or patients on dialysis as the glycemic efficacy of dapagliflozin is dependent on renal function (see 4.2 Recommended Dose and Dosage Adjustment, Renal Impairment, 8 ADVERSE REACTIONS, and 14 CLINICAL TRIALS). In such patients, dapagliflozin did not improve glycemic control and adverse reactions were more frequent (see 8 ADVERSE REACTIONS). M-DAPAGLIFLOZIN is contraindicated in patients with an eGFR less than 30 mL/min/1.73m², ESRD, or patients on dialysis (see 2 CONTRAINDICATIONS).

Before initiating M-DAPAGLFLOZIN, consider factors that may predispose patients to acute kidney injury including hypovolemia, chronic renal insufficiency, congestive heart failure and concomitant medications (diuretics, ACE inhibitors, ARBs, NSAIDs). Consider temporarily discontinuing M-DAPAGLIFLOZIN in any setting of reduced oral intake (such as acute illness or fasting) or fluid losses (such as gastrointestinal illness or excessive heat exposure); monitor patients for signs and symptoms of acute kidney injury. If acute kidney injury occurs, discontinue M-DAPAGLIFLOZIN.

7.1 Special Populations

7.1.1 Pregnant Women

M-DAPAGLIFLOZIN must not be used in pregnancy. In the time period corresponding to second and third trimesters of pregnancy with respect to human renal maturation, maternal exposure to dapagliflozin in rat studies was associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny. See 16 NON-CLINICAL TOXICOLOGY.

The extent of exposure in pregnancy during clinical trials is very limited.

There are no adequate and well-controlled studies of dapagliflozin in pregnant women. When pregnancy is detected, M-DAPAGLIFLOZIN should be discontinued.

7.1.2 Breast-feeding

M-DAPAGLIFLOZIN must not be used by a nursing woman. Studies in rats have shown excretion of dapagliflozin in milk. Direct and indirect exposure of dapagliflozin to weanling juvenile rats and during late pregnancy are each associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny, although the long-term functional consequences of these effects are unknown. These periods of exposure coincide with a critical window of renal maturation in rats. As functional maturation of the kidneys in humans continues in the first 2 years of life, dapagliflozin-associated dilated renal pelvis and tubules noted in juvenile rats could constitute potential risk for human renal maturation during the first 2 years of life. Additionally, the negative effects on body weight gain associated with lactational exposure in weanling juvenile rats suggest that dapagliflozin must be avoided during the first 2 years of life. See 16 NON-CLINICAL TOXICOLOGY.

It is unknown whether dapagliflozin and/or its metabolite are excreted in human milk. Precaution should be exercised because many drugs can be excreted in human milk.

7.1.3 Pediatrics

Pediatrics (<18 years of age): Safety and effectiveness of dapagliflozin in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

Geriatrics (≥65 years of age): A total of 2403 (26%) of the 9339 treated patients were 65 years and over and 327 (3.5%) patients were 75 years and over in the pool of 21 double-blind, controlled clinical safety and efficacy studies of dapagliflozin in patients with T2DM for improving glycemic control. After controlling for renal function (eGFR), there was no conclusive evidence suggesting that age is an independent factor affecting efficacy. No dosage adjustment is required in patients ≥65 years of age. However, in patients ≥65 years of age, a higher proportion of patients treated with dapagliflozin had adverse events related to volume depletion and renal impairment or failure compared with placebo. The most commonly reported adverse events related to renal impairment or failure in patients ≥65 years of age in any treatment group were creatinine renal clearance decreased, renal impairment, and increased blood creatinine. Older patients are more likely to have impaired renal function. See 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests and 8 ADVERSE REACTIONS.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Clinical trials of dapagliflozin to improve glycemic control

The overall incidence of adverse events in a 12-study, short-term, placebo-controlled pool (short-term treatment) in T2DM patients treated with dapagliflozin 5 mg and 10 mg for glycemic control was 61.9% and 61.5%, respectively compared to 56.9% for the placebo group.

The most commonly reported adverse events during treatment with dapagliflozin 5 mg or 10 mg (\geq 5%) were female genital mycotic infections, nasopharyngitis and urinary tract infections. Discontinuation of therapy due to adverse events in patients who received dapagliflozin 5 mg and 10 mg was 2.8% and 3.2%, respectively, compared to 2.5% for the placebo group. The most commonly reported events leading to discontinuation and reported in at least three (3) dapagliflozin 10 mg-treated patients were renal impairment (0.8%), decrease in creatinine clearance (0.6%), increased blood creatinine (0.3%), urinary tract infections (0.2%), and vulvovaginal mycotic infection (0.1%).

A total of 10 serious adverse drug events, assessed as related by the investigator, were reported in 9 patients in the short-term, placebo-controlled pool: 2 reports from patients taking dapagliflozin 5 mg daily (change of bowel habit, hypoglycemia), 2 reports from patients taking dapagliflozin 10 mg daily (constipation, rotator cuff syndrome) and 6 reports from patients in the placebo group (thrombocytopenia, acute myocardial infarction, cystitis, pyelonephritis, overdose and loss of consciousness).

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Dapagliflozin has been evaluated in clinical trials in patients with T2DM. The overall safety profile of dapagliflozin was consistent across the studies. DKA was observed in patients with T2DM.

Clinical Trials in Patients with T2DM Treated for Glycemic Control

Three major pools of patients with T2DM, who were being treated for glycemic control, were used to evaluate adverse reactions with dapagliflozin 5 mg and 10 mg versus control, including two placebo-controlled study pools and a larger pool of active- and placebo-controlled studies.

Placebo-Controlled Studies for Dapagliflozin 5 mg and 10 mg: The first pool of patients was derived from 12 placebo-controlled studies ranging from 12 to 24 weeks. In 4 studies, dapagliflozin was used as monotherapy, and in 8 studies dapagliflozin was used as add-on to background antidiabetic therapy or as combination therapy with metformin. These data reflect

exposure of 2338 patients to dapagliflozin with a mean exposure duration of 21 weeks. Patients received placebo (N=1393), dapagliflozin 5 mg (N=1145), or dapagliflozin 10 mg (N=1193) once daily.

Pool of 13 Placebo-Controlled Studies for dapagliflozin 10 mg: The safety and tolerability of dapagliflozin 10 mg was also evaluated in a larger placebo-controlled study pool. This pool combined 13 placebo-controlled studies, including 3 monotherapy studies, 9 add-on to background antidiabetic therapy studies, and an initial combination with metformin study. Across these 13 studies, 2360 patients were treated once daily with dapagliflozin 10 mg for a mean duration of exposure of 22 weeks.

Active- and Placebo-Controlled Studies: The third pool of patients was derived from 21 activeand placebo-controlled studies used to evaluate and present data for malignancies and liver tests. In this pool, 5936 patients were treated with dapagliflozin and 3403 were treated with control (either as monotherapy or in combination with other antidiabetic therapies).

The adverse events in the 12-study placebo-controlled pooled analysis reported in $\geq 2\%$ of T2DM patients treated with dapagliflozin 5 mg or 10 mg for glycemic control, and occurring more frequently than in patients treated with placebo, are shown in Table 2.

Curtum annu dan	(Pool of 1	% of Patients (Pool of 12 Placebo-controlled Studies)			
System organ class Preferred term	dapagliflozin 5 mg N=1145	dapagliflozin 10 mg N=1193	Placebo N=1393		
Gastrointestinal disorders					
Constipation	2.2	1.9	1.5		
Nausea	2.8	2.5	2.4		
Infections and infestations					
Influenza	2.7	2.3	2.3		
Nasopharyngitis	6.6	6.3	6.2		
Female genital mycotic infection ⁺	8.4	6.9	1.5		
Male genital mycotic infection [‡]	2.8	2.7	0.3		
Urinary Tract Infection [§]	5.7	4.3	3.7		
Metabolism and nutrition disorders					
Dyslipidemia	2.1	2.5	1.5		
Musculoskeletal and Connective Tissue					

Table 2 - Adverse Events Reported in ≥2% of T2DM Patients Treated for Glycemic Control with dapagliflozin 5 mg or 10 mg and More Frequently than in Patients Treated with Placebo

Table 2 - Adverse Events Reported in ≥2% of T2DM Patients Treated for Glycemic Control with
dapagliflozin 5 mg or 10 mg and More Frequently than in Patients Treated with Placebo

Sustan arran dass	% of Patients (Pool of 12 Placebo-controlled Studies)			
System organ class Preferred term	dapagliflozin 5 mg N=1145	dapagliflozin 10 mg N=1193	Placebo N=1393	
Disorders				
Back pain	3.1	4.2	3.2	
Pain in extremity	2.0	1.7	1.4	
Renal and Urinary disorders				
Increased urination ¹	2.9	3.8	1.7	
Discomfort with urination	1.6	2.1	0.7	

 Genital mycotic infections include the following preferred terms, listed in order of frequency reported for females: vulvovaginal mycotic infection, vaginal infection, vulvovaginal candidiasis, vulvovaginitis, genital infection, genital candidiasis, fungal genital infection, vulvitis, genitourinary tract infection, vulval abscess, and vaginitis bacterial (N for females: dapagliflozin 5 mg=581, dapagliflozin 10 mg=598, Placebo=677).

- Genital mycotic infections include the following preferred terms, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection and posthitis (N for males: dapagliflozin 5 mg=564, dapagliflozin 10 mg=595, Placebo=716).
- § Urinary tract infections include the following preferred terms, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.

¶ Increased urination includes the following preferred terms, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.

Additional adverse events in \geq 5% of T2DM patients, treated with dapagliflozin for glycemic control, seen more frequently than in patients in the placebo/comparator group, and reported in at least three or more patients treated with dapagliflozin 5 mg or 10 mg are described below by treatment regimen.

Table 3 - Adverse Events Reported in ≥5% of T2DM Patients Treated with dapagliflozin 5 mg or 10 mg for Glycemic Control and Observed More Frequently than in Patients Treated with Placebo/Comparator and Reported in at least Three or More Patients Treated with dapagliflozin 5 mg or 10 mg

Treature and Deciment	n (%) of Patients				
Treatment Regimen Adverse Event (Preferred term)	Dapagliflozin 5 mg	Dapagliflozin 10 mg	Placebo/ Comparator		
Monotherapy	N=132	N=146	N=75		
Diarrhea	8 (6.1)	4 (2.7)	1 (1.3)		
Upper respiratory infection	2 (1.5)	9 (6.2)	1 (1.3)		
Arthralgia	8 (6.1)	7 (4.8)	1 (1.3)		
Headache	12 (9.1)	13 (8.9)	5 (6.7)		
Add-on to Metformin	N=137	N=135	N=137		
Diarrhea	5 (3.6)	10 (7.4)	7 (5.1)		
Headache	10 (7.3)	11 (8.1)	6 (4.4)		
	Dapagliflozi				
Add-on to Metformin versus Glipizide	N=	N=408			
Headache	21	21 (5.2)			

Description of Selected Adverse Reactions in T2DM Patients Being Treated for Glycemic Control:

Volume Depletion and Hypotension

Events related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) were reported in 0.6%, 0.8% and 0.4% of patients who received dapagliflozin 5 mg, dapagliflozin 10 mg and placebo, respectively, in the 12-study, short-term, placebo-controlled pool. Serious events occurred in $\leq 0.2\%$ of patients across the 21 active- and placebo-controlled studies and were balanced between dapagliflozin 10 mg and comparator.

Postural blood pressure measurement revealed orthostatic hypotension in 13.1% of patients treated with dapagliflozin 10 mg vs. 11.3% of patients treated with placebo over the 24-week treatment period. In addition, in two studies with patients with T2DM and hypertension, postural blood pressure measurement revealed orthostatic hypotension in 3.2% of dapagliflozin 10 mg-treated patients vs. 1.7% of placebo-treated patients across the two studies over the 12-week treatment period.

Genital Mycotic Infections

Events of genital mycotic infections were reported in 5.7% (65/1145), 4.8% (57/1193) and 0.9% (12/1393) of patients who received dapagliflozin 5 mg, dapagliflozin 10 mg and placebo, respectively, in the 12-study, short-term, placebo-controlled pool. Infections were more

frequently reported in females (8.4% [49/581], 6.9% [41/598] dapagliflozin 5 mg and 10 mg, respectively, vs. 1.5% [10/677] placebo) than in males (2.8% [16/564], 2.7% [16/595] dapagliflozin 5 mg and 10 mg, respectively vs. 0.3% [2/716] placebo). The most frequently reported genital infections were vulvovaginal mycotic infections in females, and balanitis in males (see Table 2).

Patients who had a previous history of recurrent genital mycotic infections, were more likely to have an event of genital infection during the study than those without a history of infection (23.1%, [3/13] 25.0% [3/12] and 10.0% [1/10] versus 5.9% [60/1013], 5.0% [53/1053] and 0.8% [10/1247] on dapagliflozin 5 mg, dapagliflozin 10 mg and placebo, respectively).

Urinary Tract Infections

Events of urinary tract infections (UTI) were reported in 5.7% (65/1145), 4.3% (51/1193), and 3.7% (52/1393) of patients who received dapagliflozin 5 mg, dapagliflozin 10 mg and placebo, respectively, in the 12- study, short term, placebo-controlled pool. Infections were more frequently reported in females (9.6% [56/581] and 7.7% [46/598] dapagliflozin 5 mg and 10 mg, respectively, vs. 6.6% [45/677] placebo) than in males (1.6% [9/564] and 0.8% [5/595] dapagliflozin 5 mg and 10 mg, respectively, vs. 1.0% [7/716] placebo).

In 9 of the 13 studies in the dapagliflozin 10 mg placebo-controlled pool for which long-term treatment data were available (mean duration of treatment 439.5 days for dapagliflozin 10 mg and 419.0 days for placebo), of the 174 patients treated with dapagliflozin 10 mg who experienced an infection, 135 (77.6%) had only one and 11 (6.3%) had 3 or more. Of the 121 patients treated with placebo who experienced an infection, 94 (77.7%) had only one and 12 (9.9%) had 3 or more.

In the 13-study, short-term, placebo-controlled pool, patients who had a previous history of recurrent urinary tract infection, were more likely to have an event of urinary tract infection (6.0% [26/436] of patients with history of infection treated with dapagliflozin 10 mg and 5.9% [24/407] of patients with history of infection on placebo) during the study than those without a history of infection (4.4% [84/1924] on dapagliflozin 10 mg and 3.0% [57/1888] on placebo).

Hypoglycemia

The frequency of hypoglycemia depended on the type of background therapy used in each study (see Table 4). Studies of dapagliflozin as an add-on to sulfonylurea or as an add-on to insulin therapy had higher rates of hypoglycemia with dapagliflozin treatment than with placebo treatment. See 7 WARNINGS AND PRECAUTIONS.

Table 4 - Incidence of Major^{*} and Minor[†] Hypoglycemia in Placebo-Controlled Studies in T2DM Patients Being Treated for Glycemic Control

	dapagliflozin 5 mg	dapagliflozin 10 mg	Placebo
Monotherapy (24 weeks)	N=64	N=70	N=75
Major [n (%)]	0	0	0

	dapagliflozin	dapagliflozin	Placebo	
	5 mg	10 mg		
Minor [n (%)]	0	0	0	
Add-on to Metformin (24 weeks)	N=137	N=135	N=137	
Major [n (%)]	0	0	0	
Minor [n (%)]	2 (1.5)	1 (0.7)	0	
Active Control Add-on to Metformin vs. Glipizide (52 weeks)	-	N=406	N=408	
Major [n (%)]	-	0	3 (0.7)	
Minor [n (%)]	-	7 (1.7)	147 (36.0)	
Add-on to Glimepiride (24 weeks)	N=145	N=151	N=146	
Major [n (%)]	0	0	0	
Minor [n (%)]	8 (5.5)	9 (6.0)	3 (2.1)	
Add-on to Metformin and Sulfonylurea (24 weeks)	-	N=109	N=109	
Major [n (%)]	-	0	0	
Minor [n (%)]	-	14 (12.8)	4 (3.7)	
Add-on to Sitagliptin alone or with metformin (24 weeks)	-	N=225	N=226	
Major [n (%)]	-	1 (0.4)	0	
Minor [n (%)]	-	4 (1.8)	3 (1.3)	
Add-on to Insulin with or without other OADs (24 weeks)	N=212	N=196	N=197	
Major [n (%)]	1 (0.5)	1 (0.5)	1 (0.5)	
Minor [n (%)]	92 (43.4)	79 (40.3)	67 (34.0)	
Patients treated with Insulin	-	N=4177	N=4606	
Major [n (%)]	-	52 (1.2)	64 (1.4)	
Patients treated with a Sulfonylurea	-	N=4118	N=4521	
Major [n(%)]	-	14 (0.3)	23 (0.5)	

Table 4 - Incidence of Major^{*} and Minor[†] Hypoglycemia in Placebo-Controlled Studies in T2DM Patients Being Treated for Glycemic Control

Major episodes of hypoglycemia were defined as symptomatic episodes requiring external (third party) assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value <3 mmol/L and prompt recovery after glucose or glucagon administration.

+ Minor episodes of hypoglycemia were defined as either a symptomatic episode with a capillary or plasma

glucose measurement <3.5 mmol/L regardless of need for external assistance or an asymptomatic capillary or plasma glucose measurement <3.5 mmol/L which did not qualify as a major episode.

+ OAD = oral antidiabetic therapy.

Monotherapy and add-on to metformin: In studies with dapagliflozin used as monotherapy, addon to metformin, and initial combination with metformin for up to 102 weeks, there were no major episodes of hypoglycemia reported. In these studies, the frequency of minor episodes of hypoglycemia was similar (<5%) across the treatment groups, including placebo.

In an add-on to metformin study that compared dapagliflozin to glipizide up to 104 weeks, there were 3 episodes (0.7%) of major hypoglycemia in patients treated with glipizide plus metformin and none in patients treated with dapagliflozin plus metformin. Minor episodes of hypoglycemia were reported in 2.5% of patients treated with dapagliflozin plus metformin and 42.4% of patients treated with glipizide plus metformin.

Add-on to sulfonylureas: In a study with dapagliflozin added on to glimepiride for up to 48 weeks there was one episode of major hypoglycemia reported in a patient treated with dapagliflozin 2.5 mg plus glimepiride. Minor episodes of hypoglycemia were reported in 8.3% and 7.9% of patients treated with dapagliflozin 5 mg and 10 mg plus glimepiride, respectively, and 2.1% of patients treated with placebo plus glimepiride.

Add-on to metformin and to a sulfonylurea: In the add-on to combination study with metformin and a sulfonylurea up to 52 weeks, there were no episodes of major hypoglycemia reported. Minor episodes of hypoglycemia were reported for 15.6% of patients treated with dapagliflozin 10 mg plus metformin and a sulfonylurea and 4.6% of patients treated with placebo plus metformin and a sulfonylurea.

Add-on to sitagliptin alone or with metformin: In a study of dapagliflozin 10 mg added on to sitagliptin (with or without metformin) for up to 48 weeks, one major episode of hypoglycemia was reported in a patient treated with dapagliflozin 10 mg plus sitagliptin (without metformin). Minor episodes of hypoglycemia were reported in 2.2% and 1.3% of patients treated with dapagliflozin 10 mg or placebo added on to sitagliptin (with or without metformin), respectively.

Add-on to insulin: At Week 104, major episodes of hypoglycemia were reported in 1.4%, 1.0% and 0.5% of patients treated with dapagliflozin 5 mg and 10 mg or placebo added on to insulin, respectively. Minor episodes were reported in 52.8%, 53.1% and 41.6% of patients treated with dapagliflozin 5 mg or 10 mg or placebo added on to insulin, respectively. In two additional studies that also included a large proportion of patients who received insulin as background therapy (alone or with one or more oral antidiabetic treatments), the rate of minor episodes of hypoglycemia was also increased in patients treated with dapagliflozin 10 mg compared with those treated with placebo. See 14 CLINICAL TRIALS.

Patients with Renal Impairment

Safety was also assessed in two dedicated studies of T2DM patients being treated for glycemic control, with moderate renal impairment (eGFR \geq 45 to <60 mL/min/1.73m² and eGFR \geq 30 to <60 mL/min/1.73m², respectively).

In the study of patients with eGFR ≥45 to <60 mL/min/1.73m², at Week 24, dapagliflozin was

associated with changes in mean eGFR (dapagliflozin: -3.39 mL/min/1.73m² and placebo: -0.90 mL/min/1.73m²). The mean eGFR in the dapagliflozin group decreased initially (during the first 4 weeks of treatment) and remained steady for the remaining 20 weeks of treatment. At 3 weeks after termination of dapagliflozin, the mean change from baseline in eGFR in the dapagliflozin group was similar to the mean change in the placebo group (dapagliflozin: 0.57 mL/min/1.73m² and placebo: -0.04 mL/min/1.73m²). A higher proportion of subjects treated with dapagliflozin had adverse reactions of hypotension, compared with placebo.

In the study of patients with eGFR ≥30 to <60 mL/min/1.73m², at Week 52, dapagliflozin was associated with changes from baseline in mean eGFR (eGFR: dapagliflozin 5 mg: - 2.08 mL/min/1.73m², dapagliflozin 10 mg -4.46 mL/min/1.73m² and placebo - 2.58 mL/min/1.73m²). At Week 104, these changes persisted (eGFR: dapagliflozin 5 mg -1.71 mL/min/1.73m², dapagliflozin 10 mg -3.50 mL/min/1.73m² and placebo -2.38 mL/min/1.73m²). With dapagliflozin 5 mg and 10 mg, these eGFR reductions were evident at Week 1 while placebo treated patients had a slow continuous decline through Week 104.

Diabetic Ketoacidosis (DKA) in Patients with Diabetes

Cases of DKA, a serious life-threatening condition requiring urgent hospitalization, have been reported in patients with T2DM treated with dapagliflozin and other SGLT2 inhibitors. Some cases of DKA have been fatal. M-DAPAGLIFLOZIN is not indicated, and should not be used, in patients with type 1 diabetes. In some cases, the presentation of the condition was atypical, with blood glucose values only moderately elevated (<13.9 mmol/L (250 mg/dL)). See 7 WARNINGS AND PRECAUTIONS.

8.3 Less Common Clinical Trial Adverse Reactions

Patients with T2DM Being Treated for Glycemic Control (<2%)¹

Gastrointestinal disorder: dry mouth

Investigations: weight decreased

Metabolism and nutrition disorders: dehydration, hypotension, thirst

Renal and urinary disorders: glomerular filtration rate decreased, nocturia

Reproductive and breast disorders: pruritus genital, vulvovaginal pruritus

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Patients with T2DM Being Treated for Glycemic Control

Increases in Serum Creatinine, Blood Urea Nitrogen (BUN) and Decreased eGFR

In the pool of 13 placebo-controlled studies, in dapagliflozin-treated patients, mean eGFR decreased by Week 1 and then increased toward eGFR baseline values over time to Week 24.

¹ Based on medical assessment (including biological plausibility/mechanism of action) of adverse events reported in <2% of subjects in the 12- study placebo-controlled pool.

Changes from baseline in serum creatinine were consistent with changes in eGFR. Mean serum creatinine levels increased at Week 1 and decreased toward baseline at Week 24. There were small increases in BUN. Mean BUN levels increased at Week 1 and values remained stable through Weeks 24 and 102.

Study Week/	Week 1	Week 1*		Week 24*		
Treatment Group	dapagliflozin 10 mg	Placebo	dapagliflozin 10 mg	Placebo		
Serum creatinine, μmol/L (mg/dL)						
	-3.62	-0.71	1.68	0.71		
Mean Changes from Baseline	(-0.041)	(-0.008)	(0.019)	(0.008)		
Dasenne	N=1112	N=1057	N=1954	N=1844		
eGFR, mL/min/1.73m ²						
Mean Changes from	-4.174	0.490	-1.446	-0.665		
Baseline	N=1102	N=1048	N=1954	N=1844		

Table 5 - Mean Changes from Baseline for Serum Creatinine and eGFR at Week 1 and Week 24

Pool of 13 placebo-controlled studies in patients with T2DM being treated for glycemic control.

Increases in Hemoglobin/Hematocrit

In the pool of 13 placebo-controlled studies, increases from baseline in mean hemoglobin values were observed and increases from baseline in mean hematocrit values were observed in dapagliflozin-treated patients starting at Week 1 and continuing up to Week 16, when the maximum mean difference from baseline was observed. The mean changes from baseline in hemoglobin and hematocrit at Weeks 24 and 102 are presented below.

Table 6 - Mean Changes from Baseline for Hemoglobin and Hematocrit at Week 24 and Wee	ek
102	

Study Week/	Week 24*		Week 102**			
Treatment Group	dapagliflozin 10 mg	Placebo	dapagliflozin 10 mg	Placebo		
Hemoglobin, g/L (g/dL)						
	6.21	-1.38	7.0	-2.1		
Mean Changes from Baseline	(0.621)	(-0.138)	(0.70)	(-0.21)		
	N=1934	N=1828	N=621	N=515		
Hematocrit, %						
Maan Changes from Deceline	2.30	-0.33	2.68	-0.46		
Mean Changes from Baseline	N=1908	N=1796	N=616	N=510		

* Pool of 13 placebo-controlled studies in patients with T2DM being treated for glycemic control.

** Pool of 9 placebo-controlled studies in patients with T2DM being treated for glycemic control.

By Week 24, hematocrit values >55% were reported in 1.3% of dapagliflozin 10 mg-treated patients vs. 0.4% of placebo-treated patients. Results were similar during the short-term plus long-term phase (the majority of patients were exposed to treatment for more than one year).

Increases in Serum Inorganic Phosphorus

In the pool of 13 placebo-controlled studies, increases from baseline in mean serum phosphorus levels were reported at Week 24 in dapagliflozin 10 mg-treated patients compared with placebo-treated patients. Similar results were seen at Week 102 (see below). Higher proportions of patients with marked laboratory abnormalities of hyperphosphatemia were reported in dapagliflozin 10 mg group vs. placebo at Week 24 and during the short-term plus long-term phase. The clinical relevance of these findings is unknown.

Table 7 - Mean Changes from Baseline for Serum Inorganic Phosphorus and Proportion ofPatients with Hyperphosphatemia at Week 24 and Week 102

Study Week/	Week 24*		Week 102**	
Treatment Group	dapagliflozin 10 mg	Placebo	dapagliflozin 10 mg	Placebo
Serum Inorganic Phosphorus,	µmol/L (mg/dL)			
Mean Changes from	42.0	-12.9	38.7	6.5
Baseline	(0.13)	(-0.04)	(0.12)	(0.02)
	N=1954	N=1844	N=627	N=522
+ Hyperphosphatemia				
Proportion of Patients	1.7%	0.7%	3.0%	1.6%
	N=1178	N=1381	N=2001	N=1940

* Pool of 13 placebo-controlled studies in patients with T2DM being treated for glycemic control.

** Pool of 9 placebo-controlled studies in patients with T2DM being treated for glycemic control.

⁺ Defined as ≥1.81 mmol/L (≥5.6 mg/dL) if age 17-65 or ≥1.65 mmol/L (≥5.1 mg/dL) if ≥ age 66.

Lipids

In the pool of 13 placebo-controlled studies, increases from baseline were noted in levels of total cholesterol, LDL- and HDL-cholesterol, and decreases from baseline were noted for triglycerides at Week 24 and Week 102 in dapagliflozin 10 mg-treated patients compared with placebo-treated patients (see below).

Study Week/	Week 24*		Week 102**	
Treatment Group	dapagliflozin 10 mg	Placebo	dapagliflozin 10 mg	Placebo
Mean Percent Changes from Baseline				
Total Cholesterol	2.5%	0.0%	2.1%	-1.5%
	N=1851	N=1747	N=550	N=446
HDL-cholesterol	6.0%	2.7%	6.6%	2.1%
	N=1851	N=1748	N=549	N=447
LDL-cholesterol	2.9%	-1.0%	2.9%	-2.2%
	N=1840	N=1736	N=542	N=442
Triglycerides	-2.7%	-0.7%	-1.8%	-1.8%
	N=1844	N=1736	N=545	N=444

Table 8 - Mean Changes from Baseline for Lipid Parameters at Week 24 and Week 102

* Pool of 13 placebo-controlled studies in patients with T2DM being treated for glycemic control.

** Pool of 9 placebo-controlled studies in patients with T2DM being treated for glycemic control.

The ratio between LDL-cholesterol and HDL-cholesterol decreased for both treatment groups at Week 24 and at Week 102.

8.5 Post-Market Adverse Reactions

The following adverse reactions have been identified during post-approval use of dapagliflozin in patients with T2DM. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary: severe urinary tract infections; urosepsis and pyelonephritis

Hepatic/Biliary/Pancreatic: acute pancreatitis

Infection and Infestations: necrotizing fasciitis of the perineum (Fournier's gangrene). See 7 WARNINGS AND PRECAUTIONS.

Metabolism: diabetic ketoacidosis

Renal and Urinary Disorders: acute kidney injury, including acute renal failure

Skin and Subcutaneous Tissue Disorders: rash (including rash generalized, rash pruritic, rash macular, rash macular-papular, rash pustular and rash vesicular)

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

In vitro assessment of interactions

The metabolism of dapagliflozin is primarily mediated by UGT1A9-dependent glucuronide

conjugation. The major metabolite, dapagliflozin 3-O-glucuronide, is not an SGLT2 inhibitor.

In *in vitro* studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, 3A4, nor induced CYP1A2, 2B6 or 3A4. Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter. Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates.

9.3 Drug-Behavioural Interactions

The effects of smoking, diet, and alcohol use on the pharmacokinetics of dapagliflozin have not been specifically studied.

9.4 Drug-Drug Interactions

Pharmacokinetic Interactions

Effect of other drugs on dapagliflozin: In studies conducted in healthy subjects, the pharmacokinetics of dapagliflozin were not altered by the coadministered drugs (see Table 9).

Coadministered Drug (Dose Regimen)*	Dapagliflozin (Dose Regimen)*	Effect on Dapagliflozin Exposure Ratio of Adjusted Geometric Means (90% CI)		Clinical Comment
		C _{max}	AUC [†]	-
Oral Antidiabetic Agents				
Metformin (1000 mg)	20 mg	0.932	0.995	No dosing
		(0.848, 1.024)	(0.945, 1.053)	adjustment required
Pioglitazone (45 mg)	50 mg	1.09	1.03	No dosing
		(1.00, 1.18)	(0.98, 1.08)	adjustment required
Sitagliptin (100 mg)	20 mg	0.958	1.081	No dosing
		(0.875, 1.049)	(1.031, 1.133)	adjustment required
Glimepiride (4 mg)	20 mg	1.006	0.989	No dosing
		(0.921, 1.097)	(0.958, 1.020)	adjustment required
Voglibose (0.2 mg three	10 mg	1.040	1.009	No dosing

Table 9 - Effects of Coadministered Drugs on Dapagliflozin Systemic Exposure

Coadministered Drug (Dose Regimen)*	Dapagliflozin (Dose Regimen)*	Effect on Dapagliflozin Exposure Ratio of Adjusted Geometric Means (90% Cl)		Clinical Comment
		C _{max}	AUC [†]	_
times daily)		(0.899, 1.204)	(0.954, 1.067)	adjustment required
Other Medications				
Hydrochlorothiazide	50 mg	NC	1.07	No dosing
(25 mg)			(1.04, 1.11)	adjustment required
Bumetanide (1 mg)	10 mg once daily for	1.080	1.047	No dosing
	7 – 14 days	(0.953, 1.222)	(0.991, 1.106)	adjustment required
Valsartan (320 mg)	20 mg	0.881	1.024	No dosing
		(0.796, 0.975)	(1.000, 1.049)	adjustment required
Simvastatin (40 mg)	20 mg	0.978	0.986	No dosing
		(0.887, 1.078)	(0.957, 1.017)	adjustment required
Mefenamic acid (250 mg	10 mg	1.13	1.51	No dosing
every 6 hours)		(1.03, 1.24)	(1.44, 1.58)	adjustment required
Anti-infective Agent				
Rifampin (600 mg once	10 mg	0.931	0.780	No dosing
daily for 6 days)**		(0.779, 1.112)	(0.731, 0.832)	adjustment required

Table 9 - Effects of Coadministered Drugs on Dapagliflozin Systemic Exposure

* Single dose unless otherwise noted.

NC No apparent change, ratio and 90% CI were not calculated.

+ AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.

** The mean amount of glucose excreted in the urine over 24 h following administration of dapagliflozin alone (51 g) was not markedly affected by rifampin coadministration (45 g).

Effect of dapagliflozin on other drugs: In studies conducted in healthy subjects, as described below, dapagliflozin did not alter the pharmacokinetics of the coadministered drugs (see Table 10).

Coadministered Drug (Dose Regimen)*	Dapagliflozin (Dose Regimen)*	Effect on Coadministered Drug Exposure Ratio of Adjusted Geometric Means (90% CI)		Clinical Comment	
		C _{max}	AUC [†]	-	
Oral Antidiabetic Agents					
Metformin (1000 mg)	20 mg	0.953	1.001	No dosing	
		(0.866, 1.049)	(0.933, 1.075)	adjustment required	
Pioglitazone (45 mg)	50 mg	0.93	1.00	No dosing	
		(0.75, 1.15)	(0.90, 1.13)	adjustment required	
Sitagliptin (100 mg)	20 mg	0.887	1.012	No dosing	
		(0.807, 0.974)	(0.985, 1.040)	adjustment required	
Glimepiride (4 mg)	20 mg	1.043	1.132	No dosing	
		(0.905, 1.201)	(0.996, 1.287)	adjustment required	
Other Medications					
Hydrochlorothiazide (25 mg)	50 mg	NC	0.99	No dosing	
			(0.95, 1.04)	adjustment required	
Bumetanide (1 mg)**	10 mg once daily	1.132	1.132	No dosing	
	for 7 days	(0.979, 1.310)	(0.985, 1.302)	adjustment required	
Valsartan (320 mg)	20 mg	0.938	1.046	No dosing	
		(0.762, 1.156)	(0.850, 1.286)	adjustment required	
Simvastatin (40 mg)	20 mg	0.936	1.193	No dosing	
		(0.816, 1.073)	(1.018, 1.399)	adjustment required	
Digoxin (0.25 mg)	20 mg loading dose	0.990	1.002	No dosing	
	then 10 mg once	(0.843, 1.162)	(0.860, 1.167)	adjustment	

Table 10 - Effects of Dapagliflozin on the Systemic Exposures of Coadministered Drugs

Coadministered Drug (Dose Regimen)*	Dapagliflozin (Dose Regimen)*	Effect on Coadministered Drug Exposure Ratio of Adjusted Geometric Means (90% CI)		Clinical Comment
		C _{max}	AUC ⁺	-
	daily for 7 days			required
Warfarin (25 mg)***	20 mg loading dose	S-wa	rfarin	No dosing
	then 10 mg once daily for 7 days	1.030 (0.994, 1.124)	1.068 (1.002, 1.138)	adjustment required
		R-wa	rfarin	
		1.057 (0.977, 1.145)	1.079 (1.030, 1.130)	

Table 10 - Effects of Dapagliflozin on the Systemic Exposures of Coadministered Drugs

* Single dose unless otherwise noted.

NC No apparent change, ratio and 90% CI were not calculated.

+ AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.

** Coadministration of dapagliflozin did not meaningfully alter the steady-state pharmacodynamic responses (urinary sodium excretion, urine volume) to bumetanide in healthy subjects.

*** Dapagliflozin also did not affect the anticoagulant activity of warfarin as measured by the prothrombin time (International Normalized Ratio; [INR]).

Pharmacodynamic Interactions

Diuretics: M-DAPAGLIFLOZIN may add to the diuretic effect of loop diuretics and may increase the risk of dehydration and hypotension. See 7 WARNINGS AND PRECAUTIONS.

9.5 Drug-Food Interactions

Interactions with food have not been studied.

9.6 Drug-Herb Interactions

The effects of herbal products on the pharmacokinetics of dapagliflozin have not been studied.

9.7 Drug-Laboratory Test Interactions

Due to its mechanism of action, patients taking M-DAPAGLIFLOZIN will test positive for glucose in their urine. Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Dapagliflozin has been shown in vitro to be a potent, competitive and reversible inhibitor of

sodium-glucose co-transporter 2 (SGLT2). Dapagliflozin improves glycemic control in patients with T2DM by reducing renal glucose reabsorption leading to urinary excretion of excess glucose (glucuresis). The major human metabolite of dapagliflozin, dapagliflozin 3-O-glucuronide, is 2500-fold less active at SGLT2 and is not expected to have pharmacologic activity at clinically relevant doses.

Effect on Blood Glucose

SGLT2 is selectively expressed in the kidney. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. In patients with T2DM, dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary excretion of excess glucose. The amount of glucose removed by the kidney through this mechanism is dependent upon the blood glucose concentration and GFR. Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycemia. Dapagliflozin acts independently of insulin secretion and insulin action.

Urinary glucose excretion (glucuresis) induced by dapagliflozin is associated with caloric loss and reduction in weight. Inhibition of glucose and sodium co-transport by dapagliflozin is also associated with mild diuresis and transient natriuresis.

The Ki (inhibition constant) value for human SGLT2 is 0.2 nM. Dapagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is greater than 1400 times more selective for SGLT2 vs. SGLT1, the major transporter in the gut responsible for glucose absorption. Dapagliflozin is also highly selective for SGLT2 vs. the facilitative glucose transporters GLUT1, GLUT2 and GLUT4.

10.2 Pharmacodynamics

Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with T2DM following the administration of dapagliflozin. Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in patients with T2DM for 12 weeks. This glucose elimination rate approached the maximum glucose excretion observed at 20 mg/day of dapagliflozin. Evidence of sustained glucose excretion was seen in patients with T2DM given dapagliflozin 10 mg/day for up to 2 years.

This urinary glucose excretion with dapagliflozin also results in osmotic diuresis and increases in urinary volume. Urinary volume increases in patients with T2DM treated with dapagliflozin 10 mg were sustained at 12 weeks and amounted to approximately 375 mL/day. The increase in urinary volume was associated with a small and transient increase in urinary sodium excretion that was not associated with changes in serum sodium concentrations.

Urinary uric acid excretion was also increased transiently (for 3-7 days) and accompanied by a reduction in serum uric acid concentration. At 24 weeks, reductions in serum uric acid concentrations ranged from 18.3 to 48.3 μ mol/L (0.33 mg/dL to 0.87 mg/dL).

Cardiac electrophysiology: In a double-blind, randomized, placebo- and positive-controlled crossover study, single oral doses of dapagliflozin 20 mg and 150 mg were not associated with clinically or statistically significant effects on the QTc interval, the QRS duration, the PR interval,

or heart rate in healthy subjects (n=36).

10.3 Pharmacokinetics

Absorption: Dapagliflozin was rapidly and well absorbed after oral administration and can be administered with or without food. Geometric mean steady-state dapagliflozin C_{max} and AUC_{τ} values following once daily 10 mg doses of dapagliflozin were 158 ng/mL and 628 ng.h/mL, respectively. Maximum dapagliflozin plasma concentrations (C_{max}) were usually attained within 2 hours after administration in the fasted state. The C_{max} and AUC values increased proportionally to the increment in dapagliflozin dose. The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78%. Food had relatively modest effects on the pharmacokinetics of dapagliflozin in healthy subjects. Administration with a high-fat meal decreased dapagliflozin's C_{max} by up to 50% and prolonged T_{max} by approximately 1 hour, but did not alter AUC as compared with the fasted state. These changes are not considered to be clinically meaningful.

Distribution: Dapagliflozin is approximately 91% protein bound. Protein binding was not altered in various disease states (e.g., renal or hepatic impairment).

Metabolism: Dapagliflozin is a C-linked glucoside, meaning the aglycone component is attached to glucose by a carbon-carbon bond, thereby conferring stability against glucosidase enzymes. The mean plasma terminal half-life ($t_{1/2}$) for dapagliflozin was 12.9 hours following a single oral dose of dapagliflozin 10 mg to healthy subjects. Dapagliflozin is extensively metabolized, primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite. Dapagliflozin 3-O-glucuronide accounted for 61% of a 50 mg [14C]-dapagliflozin dose and was the predominant drug-related component in human plasma, accounting for 42% (based on AUC_[0-12 h]) of total plasma radioactivity, similar to the 39% contribution by parent drug. Based on AUC, no other metabolite accounted for >5% of the total plasma radioactivity at any time point measured. Dapagliflozin 3-O-glucuronide or other metabolites do not contribute to the glucose-lowering effects. The formation of dapagliflozin 3-O-glucuronide is mediated by UGT1A9, an enzyme present in the liver and kidney, and CYP-mediated metabolism was a minor clearance pathway in humans.

Elimination: Dapagliflozin and related metabolites are primarily eliminated via urinary excretion, of which less than 2% is unchanged dapagliflozin. After administration of 50 mg [14C]-dapagliflozin dose, 96% was recovered, 75% in urine and 21% in feces. In feces, approximately 15% of the dose was excreted as parent drug.

Special Populations and Conditions

- **Pediatrics:** Pharmacokinetics in the pediatric and adolescent population have not been studied.
- Age/Geriatrics: No dosage adjustment for dapagliflozin is recommended on the basis of age. The effect of age (young: ≥18 to <40 years [n=105] and elderly: ≥65 years [n=224]) was evaluated as a covariate in a population pharmacokinetic model and compared to patients ≥40 to <65 years using data from healthy subject and T2DM patient studies. The mean dapagliflozin systemic exposure (AUC) in young patients was estimated to be 10.4% lower

than in the reference group (90% CI: 87.9, 92.2%) and 25% higher in elderly patients compared to the reference group (90% CI: 123, 129%). These differences in systemic exposure were considered not to be clinically meaningful.

- **Gender:** No dosage adjustment is recommended for dapagliflozin on the basis of gender. Gender was evaluated as a covariate in a population pharmacokinetic model using data from healthy subject and T2DM patient studies. The mean dapagliflozin AUC_{ss} in females (n=619) was estimated to be 22% higher than in males (n=634) (90% CI: 117,124).
- Ethnic origin: No dosage adjustment is recommended on the basis of race. Race (white, black or Asian) was evaluated as a covariate in a population pharmacokinetic model using data from healthy subject and T2DM patient studies. Differences in systemic exposures between these races were small. Compared to whites (n=1147), Asian subjects (n=47) had no difference in estimated mean dapagliflozin systemic exposures (90% CI range 3.7% lower, 1% higher). Compared to whites, black subjects (n=43) had 4.9% lower estimated mean dapagliflozin systemic exposures.
- Body weight: No dose adjustment is recommended on the basis of weight. In a population pharmacokinetic analysis using data from healthy subject and T2DM patient studies, systemic exposures in high body weight subjects (≥120 kg, n=91) were estimated to be 78.3% (90% CI: 78.2, 83.2%) of those of reference subjects with body weight between 75 and 100 kg. No dose adjustment from the proposed dose of 10 mg dapagliflozin once daily in T2DM patients with high body weight (≥120 kg) is recommended. Subjects with low body weights (<50 kg) were not well represented in the healthy subject and patient studies used in the population pharmacokinetic analysis. Therefore, dapagliflozin systemic exposures were simulated with a large number of subjects. The simulated mean dapagliflozin systemic exposures in low body weight. Based on these findings no dose adjustment from the proposed dose of 10 mg dapagliflozin once daily in T2DM patients with low body weight. Based on these findings no dose adjustment from the proposed dose of 10 mg dapagliflozin dose adjustment from the proposed dose of 10 mg dapagliflozin once daily in T2DM patients with low body weight. Based on these findings no dose adjustment from the proposed dose of 10 mg dapagliflozin once daily in T2DM patients with low body weight (<50 kg) is recommended.
- Renal insufficiency: At steady-state (20 mg once-daily dapagliflozin for 7 days), patients with T2DM and mild, moderate or severe renal impairment (as determined by iohexol clearance) had mean systemic exposures of dapagliflozin that were 32%, 60% and 87% higher, respectively, than those of patients with T2DM and normal renal function. Higher systemic exposures to dapagliflozin in patients with T2DM and renal impairment did not result in a correspondingly higher renal glucose clearance or total cumulative glucose excretion. The renal glucose clearance and 24-hour glucose excretion were lower in patients with moderate or severe renal impairment as compared to patients with normal and mild renal impairment. The steady-state 24-hour urinary glucose excreted by patients with T2DM and normal renal function and 85, 52, 18 and 11 g of glucose/day was excreted by patients with T2DM and normal renal function or mild, moderate or severe renal impairment, respectively. There were no differences in the protein binding of dapagliflozin between renal impairment groups or compared to healthy subjects. The impact of hemodialysis on dapagliflozin exposure is not known.

• Hepatic insufficiency: A single dose (10 mg) dapagliflozin clinical pharmacology study was conducted in patients with mild, moderate or severe hepatic impairment (Child-Pugh classes A, B, and C, respectively) and healthy matched controls. There were no differences in the protein binding of dapagliflozin between patients with hepatic impairment compared to healthy subjects. In patients with mild or moderate hepatic impairment mean C_{max} and AUC of dapagliflozin were up to 12% and 36% higher, respectively, compared to healthy matched control subjects. In patients with severe hepatic impairment (Child-Pugh class C) mean C_{max} and AUC of dapagliflozin were up to 40% and 67% higher than matched healthy controls, respectively.

11 STORAGE, STABILITY AND DISPOSAL

Store at room temperature (15-30°C).

12 SPECIAL HANDLING INSTRUCTIONS

Store in a safe place and out of the reach of children.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug Substance

Common name: dapagliflozin

Chemical name: (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Molecular formula and molecular mass: C21H25ClO6; 408.87 g/mol

Structural formula:



Physicochemical properties: Dapagliflozin is a white to pale yellow colour, highly hygroscopic powder. The substance comes in the amorphous form, and it is freely soluble in methanol, ethanol, dimethyl sulfoxide and N,N-dimethyl formamide. It is slightly soluble in water.

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Study #	Trial design	Dosage, route of administration and duration	N per group/ N treated with dapagliflozin/ Total	Mean age	Gender (% M/F)
	Clinical Tria	als in Patients with T2DM Tre	ated for Glycemic Cor	itrol	
Monothe	rapy				
1	Multicentre, randomized, double-blind, placebo-controlled	<u>Group 1</u> : dapagliflozin 2.5, 5 or 10 mg, QAM or QPM, vs. placebo Oral, 24 weeks + 78 weeks	64 - 76/ 410/ 485 (ST)	52.6	47/53

Table 11 - Summary of patient demographics for clinical trials in specific indications

Study #	Trial design	Dosage, route of administration and duration	N per group/ N treated with dapagliflozin/ Total	Mean age	Gender (% M/F)
		Group 2: dapagliflozin 5 or 10 mg, QAM	34, 39/ 73/	48.1	64/36
		Oral, 24 weeks + 78 weeks	73 (ST)		
Add-on C	ombination Therapy	with Metformin			
2	Multicentre, randomized,	4 groups: dapagliflozin 2.5, 5, or 10 mg or placebo	135 - 137/ 409/	53.9	53/47
	double-blind, placebo-controlled	Background therapy: metformin ≥ 1500 mg/day	546 (ST)		
		Oral, 24 weeks + 78 weeks			
3	Multicentre, randomized, double-blind, active-controlled	2 groups: dapagliflozin titrated dose of 2.5, 5, or 10 mg or glipizide titrated dose of 5, 10, or 20 mg Background therapy: metformin ≥1500 mg	406 - 408/ 406/ 814 (ST)	58.4	55/45
		Oral, 52 weeks + 52 weeks + 52 weeks			
Add-on C	ombination Therapy	with a Sulfonylurea			
4	Multicentre, randomized, double-blind, placebo-controlled	4 groups: dapagliflozin 2.5, 5, or 10 mg or placebo Background therapy: glimepiride 4 mg/day	146 - 154/ 450/ 596 (ST)	59.8	48/52
		Oral, 24 weeks + 24 weeks			
Add-on C	ombination Therapy	with Metformin and a Sulfon	ylurea		
5	Multicentre, randomized, double-blind, placebo-controlled	2 groups: dapagliflozin 10 mg or placebo Background therapy: metformin ≥1500 mg and a sulfonylurea (at maximum tolerated dose and≥50% of maximum recommended dose)	109/ 109/ 218 (ST)	61.0	49/51
		Oral, 24 weeks + 28 weeks			
Add-on C	ombination Therapy	with Sitagliptin Alone or with	Metformin		

Table 11 - Summary of patient demographics for clinical trials in specific indications

Study #	Trial design	Dosage, route of administration and duration	N per group/ N treated with dapagliflozin/ Total	Mean age	Gender (% M/F)
6	Multicentre, randomized, double-blind, placebo-controlled	2 groups: dapagliflozin 10 mg or placebo Background therapy: Sitagliptin 100 mg/day (+/- metformin ≥1500 mg) Oral, 24 weeks + 24 weeks	225 - 226/ 225/ 451 (ST)	55.0	55/45
Add-on C	ombination Therapy	with Insulin			
7	Multicentre, randomized, double-blind, placebo-controlled	4 groups: dapagliflozin 2.5, 5, or 10 mg or placebo Background therapy: insulin≥30 IU/day ± maximum 2 OAD	196 - 212/ 610/ 807 (ST)	59.3	48/52
		In LT, forced titration of dapagliflozin 5 mg to 10 mg Oral, 24 weeks + 24 weeks + 56 weeks			

Table 11 - Summary of patient demographics for clinical trials in specific indications

LT = long-term; OAD = oral anti-diabetic drug; QAM = once in the morning; QPM = once in the evening; ST = short-term.

Clinical Trials in Patients with T2DM Treated for Glycemic Control

Dapagliflozin was studied as monotherapy and in combination with other antidiabetic medications, including metformin, glimepiride, or insulin.

Treatment with dapagliflozin as monotherapy and in combination with metformin, glimepiride, or insulin produced clinically relevant and statistically significant improvements in mean change from baseline at Week 24 in HbA1c, fasting plasma glucose (FPG), and 2-hour post-prandial glucose (PPG) (where measured), compared to placebo or control. The estimated, placebo-adjusted, HbA1c reduction across trials and doses ranged from 0.40% to 0.84%. These glycemic effects were sustained in long-term extensions up to 104 weeks. HbA1c reductions were seen across subgroups including gender, age, race, duration of disease, and baseline body mass index (BMI). In addition, patients treated with dapagliflozin compared to placebo or control achieved greater HbA1c reductions in patients with a baseline HbA1c ≥9%.

14.2 Study Results

Clinical Trials in Patients with T2DM Treated for Glycemic Control

Monotherapy (Study 1)

The efficacy and safety of dapagliflozin as monotherapy was evaluated in a double-blind, placebo-controlled study of 24 weeks duration in treatment-naïve patients. Following a 2-week

diet and exercise placebo lead-in period, 485 patients with HbA1c \geq 7% and \leq 10% were randomized to dapagliflozin 2.5 mg, 5 mg, or 10 mg once daily in either the morning (QAM, main cohort) or evening (QPM), or placebo in the morning only.

As shown in Table 12, statistically significant reductions (p<0.001) in HbA1c and FPG relative to placebo were observed with dapagliflozin 5 mg and 10 mg QAM at Week 24 which were sustained long term. Overall, the PM administration of dapagliflozin had a comparable safety and efficacy profile to dapagliflozin administered in the AM.

Efficacy Parameter	dapagliflozin 5 mg N=64 [†]	dapagliflozin 10 mg N=70 [†]	Placebo N=75 [†]
HbA1c (%)			
Baseline (mean)	7.83	8.01	7.79
Change from baseline (adjusted mean [‡])	-0.77	-0.89	-0.23
Difference from placebo (adjusted mean [‡]) (95% CI)	-0.54 [§] (-0.84, -0.24)	-0.66 [§] (-0.96, -0.36)	
Patients (%) achieving HbA1c <7% adjusted for baseline	44.2 [¶]	50.8 [¶]	31.6
FPG (mmol/L)			
Baseline (mean)	8.7	9.3	8.9
Change from baseline (adjusted mean [‡])	-1.3	-1.6	-0.2
Difference from placebo (adjusted mean [‡]) (95% Cl)	-1.1 [§]	-1.4 [§]	
	(-1.7, -0.5)	(-2.0, -0.8)	
Body Weight (kg)			
Baseline (mean)	87.17	94.13	88.77
Change from baseline (adjusted mean [‡])	-2.83	-3.16	-2.19
Difference from placebo (adjusted mean [‡]) (95% CI)	-0.65 (-1.90, 0.61)	-0.97 (-2.20, 0.25)	

Table 12 - Results at Week 24 (LOCF*) in a Placebo-Controlled Study of Dapagliflozin Monotherapy in Patients with Type 2 Diabetes (Main Cohort AM Doses)

* LOCF: last observation (prior to rescue for rescued patients) carried forward.

+ All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period.

Least squares mean adjusted for baseline value.

§ p-value <0.001 vs. placebo.

1 Not evaluated for statistical significance as a result of the sequential testing procedure for the secondary endpoints.

Combination Therapy:

Add-On Therapy with Metformin (Study 2)

A 24-week double-blind, placebo-controlled study was conducted to evaluate dapagliflozin in combination with metformin in patients with T2DM with inadequate glycemic control (HbA1c ≥7% and ≤10%). Patients on metformin at a dose of at least 1500 mg per day were randomized after completing a 2-week single-blind placebo lead-in period. Following the lead-in period, eligible patients were randomized to dapagliflozin 2.5 mg, 5 mg, or 10 mg, or placebo in addition to their current dose of metformin.

As shown in Table 13, statistically significant (p<0.0001) reductions in HbA1c, FPG and body weight relative to placebo were observed with dapagliflozin 5 mg and 10 mg at Week 24 which were sustained long term.

Efficacy Parameter	dapagliflozin	dapagliflozin	Placebo
	5 mg	10 mg	+ Metformin
	+ Metformin N=137 [†]	+ Metformin N=135 [†]	N=137 [†]
HbA1c (%)			
Baseline mean	8.17	7.92	8.11
Change from baseline (adjusted mean [‡])	-0.70	-0.84	-0.30
Difference from placebo (adjusted mean [‡]) (95% Cl)	-0.41 [§] (-0.61, -0.21)	-0.54 [§] (-0.74, -0.34)	
Patients (%) achieving HbA1c <7% adjusted for baseline	37.5 [¶]	40.6¶	25.9
FPG (mmol/L)			
Baseline mean	9.4	8.7	9.2
Change from baseline at week 24 (adjusted mean [‡])	-1.2	-1.3	-0.3
Difference from placebo (adjusted mean [‡]) (95%	-0.9 [§]	-1.0 [§]	
CI)	(-1.3, -0.5)	(-1.4, -0.6)	
Body Weight (kg)			
Baseline mean	84.73	86.28	87.74
Change from baseline (adjusted mean [‡])	-3.04	-2.86	-0.89
Difference from placebo (adjusted mean [‡]) (95% Cl)	-2.16 [§] (-2.81, -1.50)	-1.97 [§] (-2.63, -1.31)	

Table 13 - Results of a 24-Week (LOCF*) Placebo-Controlled Study of Dapagliflozin in Add-On Combination with Metformin

- * LOCF: last observation (prior to rescue for rescued patients) carried forward.
- + All randomized patients who took at least one dose of double -blind study medication during the short-term double- blind period.
- Least squares mean adjusted for baseline value.
- § p-value <0.0001 vs. placebo + metformin.
- ¶ p-value <0.05 vs. placebo + metformin.

Add-On Therapy with Metformin – Active-Controlled Study versus Glipizide (Study 3)

Patients with T2DM with inadequate glycemic control (HbA1c >6.5% and ≤10%) were randomized in a 52-week, double-blind, glipizide-controlled non-inferiority study to evaluate dapagliflozin as add-on therapy to metformin. Patients on metformin at a dose of at least 1500 mg per day were randomized following a 2-week placebo lead-in period to glipizide or dapagliflozin (5 mg or 2.5 mg, respectively) and were up-titrated over 18 weeks to optimal glycemic effect (FPG <110 mg/dL, <6.1 mmol/L) or to the highest dose level (up to glipizide 20 mg and dapagliflozin 10 mg) as tolerated by patients. Thereafter, doses were kept constant, except for down-titration to prevent hypoglycemia.

At the end of the titration period, 87% of patients treated with dapagliflozin had been titrated to the maximum study dose (10 mg), versus 73% treated with glipizide (20 mg). As shown in Table 14, treatment with dapagliflozin provided similar reductions in HbA1c from baseline compared to glipizide (with the upper bound of the 95% confidence interval around the between-group difference less than the pre-specified non-inferiority margin of 0.35%). Statistically significant (p<0.0001) reductions in body weight were observed with dapagliflozin compared to glipizide.

Efficacy Parameter	Dapagliflozin + Metformin N=400 [†]	Glipizide + Metformin N=401 [†]
HbA1c (%)		
Baseline (mean)	7.69	7.74
Change from baseline (adjusted mean [‡])	-0.52	-0.52
Difference from Glipizide+Metformin (adjusted mean [‡])	0.00 [¶]	
(95% CI)	(-0.11, 0.11)	
Body Weight (kg)		
Baseline (mean)	88.44	87.60
Change from baseline (adjusted mean [‡])	-3.22	1.44
Difference from Glipizide+Metformin (adjusted mean [‡])	-4.65 [§]	
(95% CI)	(-5.14, -4.17)	

Table 14 - Results at Week 52 (LOCF*) in an Active-Controlled Study comparing Dapagliflozin to Glipizide as Add-on to Metformin

* LOCF: last observation carried forward.

- + Randomized and treated patients with baseline and at least 1 post-baseline efficacy measurement.
- + Least squares mean adjusted for baseline value.
- § p-value <0.0001.
- ¶ non-inferior to glipizide + metformin.

Add-On Therapy with a Sulfonylurea (Study 4)

Patients with T2DM and inadequate glycemic control (HbA1c \geq 7% and \leq 10%) were randomized in a 24-week, double-blind, placebo-controlled study to evaluate dapagliflozin in combination with glimepiride (a sulfonylurea). Patients on at least half the maximum recommended dose of a glimepiride as monotherapy (4 mg) for at least 8 weeks lead-in were randomized to dapagliflozin 2.5 mg, 5 mg, or 10 mg or placebo in addition to glimepiride 4 mg per day. Downtitration of glimepiride to 2 mg or 0 mg was allowed for hypoglycemia during the treatment period; no up-titration of glimepiride was allowed.

As shown in Table 15, treatment with dapagliflozin 5 mg and 10 mg in combination with glimepiride provided significant reductions in HbA1c, FPG, 2-hour PPG, and body weight relative to placebo plus glimepiride at Week 24 which were sustained long term.

Efficacy Parameter	Dapagliflozin 5 mg + Glimepiride N=142 [†]	Dapagliflozin 10 mg + Glimepiride N=151 [†]	Placebo + Glimepiride N=145 [†]
HbA1c (%)			
Baseline mean	8.12	8.07	8.15
Change from baseline (adjusted mean [‡])	-0.63	-0.82	-0.13
Difference from placebo+ glimepiride (adjusted mean [‡]) (95% CI)	-0.49 [§] (-0.67, -0.32)	-0.68 [§] (-0.86, -0.51)	
Patients (%) achieving HbA1c <7% adjusted for baseline	30.3 [§]	31.7 [§]	13.0
FPG (mmol/L)			
Baseline mean	9.7	9.6	9.6
Change from baseline (adjusted mean [‡])	-1.2	-1.6	-0.1
Difference from placebo + glimepiride (adjusted mean [‡]) (95% CI)	-1.1 [§] (-1.5, -0.7)	−1.5 [§] (−1.9, −1.1)	
2-hour PPG ¹ (mmol/L)			
Baseline (mean)	17.9	18.3	18.0
Change from baseline (adjusted mean [‡])	-3.0	-3.4	-0.6

Table 15 - Results of 24 Week (LOCF*) Placebo-Controlled Study of Dapagliflozin in Combination with a Sulfonylurea (Glimepiride)

Efficacy Parameter	Dapagliflozin 5 mg + Glimepiride N=142 [†]	Dapagliflozin 10 mg + Glimepiride N=151 [†]	Placebo + Glimepiride N=145 [†]
Difference from placebo + glimepiride (adjusted mean [‡]) (95% CI)	-2.4 [§] (-3.2, -1.5)	-2.7 [§] (-3.6, -1.9)	
Body Weight (kg)			
Baseline mean	81.00	80.56	80.94
Change from baseline (adjusted mean [‡])	-1.56	-2.26	-0.72
Difference from placebo+ glimepiride (adjusted mean [‡]) (95% CI)	-0.84 ^{§§} (-1.47, -0.21)	-1.54 [§] (-2.17, -0.92)	

Table 15 - Results of 24 Week (LOCF*) Placebo-Controlled Study of Dapagliflozin in Combination with a Sulfonylurea (Glimepiride)

* LOCF: last observation (prior to rescue for rescued patients) carried forward.

+ Randomized and treated patients with baseline and at least 1 post-baseline efficacy measurement.

Least squares mean adjusted for baseline value.

§ p-value <0.0001 versus placebo.

§§ p-value 0.0091 versus placebo.

1 2-hour PPG level as a response to a 75 g oral glucose tolerance test (OGTT).

Add-On Therapy with Metformin and a Sulfonylurea (Study 5)

Patients with T2DM and inadequate glycemic control (HbA1c ≥7% and ≤10.5%) participated in a 24-week, double-blind, placebo-controlled study to evaluate dapagliflozin in combination with metformin and a sulfonylurea. Patients on a stable dose of metformin (immediate- or extended-release formulations) ≥1500 mg/day plus maximum tolerated dose, which must be at least half maximum dose, of a sulfonylurea for at least 8 weeks prior to enrolment were randomized after an 8-week placebo lead-in period to dapagliflozin 10 mg or placebo. Dose-titration of dapagliflozin or metformin was not permitted during the 24-week treatment period. Down-titration of sulfonylurea was permitted to prevent hypoglycemia during the treatment period; no up-titration of sulfonylurea was allowed.

As shown in Table 16, treatment with dapagliflozin 10 mg in combination with metformin and a sulfonylurea provided significant reductions in HbA1c, FPG and body weight relative to placebo at Week 24 which were sustained long term. At Week 8, statistically significant changes from baseline in systolic blood pressure (SBP, mmHg) of -4.0, and -0.3 were observed for dapagliflozin 10 mg, and placebo, respectively (p<0.05).

Efficacy Parameter	dapagliflozin 10 mg + Metformin + Sulphonylurea N=108 [†]	Placebo + Metformin + Sulphonylurea N=108 [†]
HbA1c (%)		
Baseline mean	8.08	8.24
Change from baseline (adjusted mean ^{‡,‡‡})	-0.86	-0.17
Difference from placebo (adjusted mean ^{‡,‡‡})	-0.69 [§]	
(95% CI)	(-0.89, -0.49)	
Patients (%) achieving HbA1c <7% adjusted for baseline	31.8 [§]	11.1
FPG (mmol/L)		
Baseline mean	9.3	10.0
Change from baseline at Week 24 (adjusted mean [‡])	-1.9	-0.04
Difference from placebo (adjusted mean [‡])	-1.86 [§]	
(95% CI)	(-2.4, -1.3)	
Body Weight (kg)		
Baseline mean	88.57	90.07
Change from baseline (adjusted mean [‡])	-2.65	-0.58
Difference from placebo (adjusted mean [‡])	-2.07 [§]	
(95% CI)	(-2.79, -1.35)	

Table 16 - Results of 24-Week (LOCF*) Placebo-Controlled Study of Dapagliflozin in Combination with Metformin and Sulfonylurea

* LOCF: last observation (prior to rescue for rescued patients) carried forward.

+ Randomized and treated patients with baseline and at least 1 post-baseline efficacy measurement.

Least squares mean adjusted for baseline value based on ANCOVA model.

the Least squares mean adjusted for baseline value based on a longitudinal repeated measures model

§ p-value <0.0001 versus placebo.

Add-On Combination Therapy with Sitagliptin Alone or in Combination with Metformin (Study 6)

A total of 452 patients with T2DM who were drug naive, or who were treated at entry with metformin or sitagliptin alone or in combination, and had inadequate glycemic control (HbA1c \geq 7.0% and \leq 10.0% at randomization), participated in a 24-week, placebo-controlled study with a 24-week extension.

Patients were stratified based on background metformin use (≥1500 mg/day) and within each stratum were randomized to either dapagliflozin 10 mg plus sitagliptin 100 mg once daily or

placebo plus sitagliptin 100 mg once daily. Endpoints were tested for dapagliflozin 10 mg versus placebo for the total study group (sitagliptin with and without metformin) and for each stratum (sitagliptin alone or sitagliptin with metformin).

As shown in Table 17, statistically significant (p<0.0001) reductions in HbA1c, FPG and body weight relative to placebo were observed with dapagliflozin 10 mg treatment for the total study group (sitagliptin with and without metformin) and for each stratum (sitagliptin alone or sitagliptin with metformin) at Week 24.

Table 17 - Results of a 24-Week (LOCF*) Placebo-Controlled Study of Dapagliflozin in Add-On
Combination with Sitagliptin with or without Metformin (Full Analysis Set and Strata without
or with Metformin)

Efficacy Parameter	dapagliflozin 10 mg + Sitagliptin + or –Met	Placebo + Sitagliptin + or –Met	dapagliflozin 10 mg + Sitagliptin	Placebo + Sitagliptin	dapagliflozin 10 mg + Sitagliptin +Met	Placebo + Sitagliptin +Met
	N=223 ⁺	N=224 [†]	N=110 ⁺	N=111 ⁺	N=113 ⁺	N=113 [†]
HbA1c (%)	N=223	N=223	N=110	N=110	N=113	N=113
Baseline (mean)	7.90	7.97	7.99	8.07	7.80	7.87
Change from baseline (adjusted mean [‡])	-0.45	0.04	-0.47	0.10	-0.43	-0.02
Difference from placebo (adjusted mean [‡]) (95% Cl)	-0.48 [§] (-0.62, -0.34)		-0.56 [§] (-0.79, -0.34)		-0.40 [§] (-0.58, -0.23)	
FPG (mmol/L)	N=222	N=222	N=110	N=110	N=112	N=112
Baseline (mean)	8.97	9.05	8.73	8.96	9.21	9.14
Change from baseline at Week 24 (adjusted mean [‡])	-1.34	0.21	-1.22	0.26	-1.45	0.17
Difference from placebo (adjusted mean [‡]) (95% Cl)	-1.55 [§] (-1.91, -1.19)		-1.47 [§] (-2.01, -0.94)		-1.62 [§] (-2.11, -1.13)	
Body Weight (kg)	N=223	N=224	N=110	N=111	N=113	N=113
Baseline (mean)	91.02	89.23	88.01	84.20	93.95	94.17
Change from baseline (adjusted mean [‡])	-2.14	-0.26	-1.91	-0.06	-2.35	-0.47
Difference from placebo (adjusted mean [‡]) (95% Cl)	-1.89 [§] (-2.37, -1.40)		-1.85 [§] (-2.47, -1.23)	mind formend	-1.87 [§] (-2.61, -1.13)	

* LOCF: last observation (prior to rescue for rescued patients) carried forward.

- + Randomized and treated patients with baseline and at least 1 post-baseline efficacy measurement.
- + Least squares mean adjusted for baseline value.
- § p-value <0.0001 versus placebo.

Add-On Therapy with Insulin (Study 7)

Patients with T2DM who had inadequate glycemic control (HbA1c ≥7.5% and ≤10.5%) were randomized in a 24-week, double-blind, placebo-controlled study to evaluate dapagliflozin as add-on therapy to insulin. Patients on a stable insulin regimen, with a mean dose of at least 30 IU of injectable insulin per day, for a period of at least 8 weeks prior and on a maximum of two oral antidiabetic medications (OADs) were randomized after completing a 2-week enrolment period to receive dapagliflozin 2.5 mg, 5 mg, or 10 mg, or placebo in addition to their current dose of insulin and other OADs, if applicable. Patients were stratified according to the presence or absence of background OADs. Up- or down-titration of insulin was only permitted during the treatment phase in patients who failed to meet specific glycemic goals. Subjects on metformin were to be on ≥1500 mg/day.

In this study, 50% (N=392) of patients were on insulin monotherapy at baseline, while 50% were on 1 or 2 OADs in addition to insulin. Of the latter, 80% (N=319) were on a background of insulin and metformin dual therapy. An inadequate number of patients on other OAD combinations were included for evaluative purposes; therefore, use with OAD combinations other than metformin alone is not indicated. In the overall patient sample 48% of patients were taking sliding scale and basal insulin, 35% were taking sliding scale insulin alone and 17% were taking basal insulin. Approximately 88% of patients completed up to Week 24. At Week 24, dapagliflozin 5 mg and 10 mg doses provided significant improvement in HbA1c and mean insulin dose, and a significant reduction in body weight compared with placebo (Table 18); the effect of dapagliflozin on HbA1c was similar in patients in both strata.

Efficacy Parameter	dapagliflozin 5 mg + Insulin N=211 [†]	dapagliflozin 10 mg + Insulin N=194 [†]	Placebo + Insulin N=193 [†]
HbA1c (%)			
Baseline mean	8.61	8.58	8.46
Change from baseline (adjusted mean [‡])	-0.82	-0.90	-0.30
Difference from placebo(adjusted mean [‡]) (95% CI)	-0.52 [§] (-0.66, -0.38)	-0.60 [§] (-0.74, -0.45)	
FPG (mmol/L)			
Baseline mean	10.3	9.6	9.4

Table 18 - Results of 24 Week (LOCF*) Placebo-Controlled Study of Dapagliflozin inCombination with Insulin with or without up to 2 Oral Antidiabetic Therapies

Efficacy Parameter	dapagliflozin 5 mg + Insulin N=211 [†]	dapagliflozin 10 mg + Insulin N=194 [†]	Placebo + Insulin N=193 [†]
Change from baseline (adjusted mean [‡])	-1.0	-1.2	0.2
Difference from placebo (adjusted mean [‡]) (95% Cl)	-1.2 (-1.7, -0.7)	−1.4 [§] (−1.9 <i>,</i> −0.9)	
Body Weight (kg)			
Baseline mean	93.20	94.63	94.21
Change from baseline (adjusted mean [‡])	-0.98	-1.67	0.02
Difference from placebo(adjusted mean [‡]) (95% Cl)	-1.00 [§] (-1.50, -0.50)	-1.68 [§] (-2.19, -1.18)	

Table 18 - Results of 24 Week (LOCF*) Placebo-Controlled Study of Dapagliflozin in Combination with Insulin with or without up to 2 Oral Antidiabetic Therapies $^{\S \S}$

* LOCF: last observation (prior to rescue for rescued patients) carried forward.

+ Randomized and treated patients with baseline and at least 1 post-baseline efficacy measurement.

Least squares mean adjusted for baseline value.

§ p-value <0.0001 versus placebo.

§§ Use with oral antidiabetic combinations other than metformin alone is not indicated.

Other Studies in Patients with T2DM Treated for Glycemic Control

Use in Patients with Type 2 Diabetes and Renal Impairment

Mild renal impairment (eGFR \geq 60 to <90 mL/min/1.73m²): Efficacy was assessed in a pooled analysis across 9 clinical studies consisting of 2226 patients with mild renal impairment. The mean change from baseline in HbA1c and the placebo-corrected mean HbA1c reduction at 24 weeks was -1.03% and -0.54%, respectively for dapagliflozin 5 mg (n=545) and -1.03% and -0.54%, respectively for dapagliflozin 10 mg (n=562). The safety profile in patients with mild renal impairment is similar to that in the overall population.

The efficacy of dapagliflozin was assessed in two dedicated studies of patients with moderate renal impairment and in a pooled analysis.

Moderate renal impairment CKD 3A (eGFR \geq 45 to <60 mL/min/1.73m²): The efficacy of dapagliflozin was assessed in a dedicated study in diabetic patients with an eGFR \geq 45 to <60 mL/min/1.73m² who had inadequate glycemic control. In a randomized, double blind, placebo-controlled trial a total of 321 adult patients with T2DM and eGFR \geq 45 to <60 mL/min/1.73m² (moderate renal impairment subgroup CKD 3A), with inadequate glycemic control, were treated with dapagliflozin 10 mg or placebo. At Week 24, dapagliflozin 10 mg (n=159) resulted in statistically significant reductions in HbA1c and body weight compared with placebo (n=161) (Table 19).

Efficacy Parameter	Dapagliflozin	Placebo	
	10 mg		
	N=159	N=161	
HbA1c (%)			
Baseline (mean)	8.35	8.03	
Change from baseline (adjusted mean [*])	-0.37 [§]	-0.03	
Difference from placebo (adjusted mean [*])	-0.34 [§]		
(95% CI)	(-0.53, -0.15)		
Body Weight (kg)			
Baseline (mean)	92.51	88.30	
% Change from baseline (adjusted mean*)	-3.42 [§]	-2.02	
Difference from placebo (adjusted mean [*])	-1.43 [§]		
(95% CI)	(-2.15, -0.69)		

Table 19 - Results at Week 24 in a Placebo-Controlled Study of DapagliflozinTreatment in Diabetic Patients with Moderate Renal Impairment (CKD 3A, eGFR ≥45 to <60 mL/min/1.73m²)

* Least squares mean adjusted for baseline value.

§ p-value <0.001.

Moderate renal impairment (eGFR \geq 30 to <60 mL/min/1.73m²): The efficacy of dapagliflozin was assessed in a study of 252 diabetic patients with eGFR \geq 30 to <60 mL/min/1.73m². Dapagliflozin treatment did not show a significant placebo corrected change in HbA1c in the overall study population at 24 weeks. In an additional analysis of the subgroup CKD 3A (eGFR \geq 45 to <60 mL/min/1.73m²), dapagliflozin 5 mg (n=35) provided a placebo-corrected mean HbA1c change at 24 weeks of -0.37% (95% CI: -0.83, 0.10), and dapagliflozin 10 mg (n=32) provided a placebo-corrected mean HbA1c change at 24 weeks of -0.33% (95% CI: -0.80, 0.14).

Efficacy in patients with moderate renal impairment was assessed in a pooled analysis across 9 clinical studies (366 patients, 87% with eGFR \geq 45 to <60 mL/min/1.73m²); this pool did not include the two dedicated studies of diabetic patients with moderate renal impairment. The mean change from baseline in HbA1c and the placebo-corrected mean HbA1c reduction at 24 weeks was -0.71% (95% CI: -0.89, -0.53) and -0.23% (95% CI: -0.47, 0.02), respectively, for dapagliflozin 5 mg (n=102) and -0.87% (95% CI: -1.07, -0.68) and -0.39% (95% CI: -0.65, -0.14), respectively, for dapagliflozin 10 mg (n=85).

Blood Pressure

At Week 24 across 11 clinical studies, treatment with dapagliflozin 10 mg decreased the placebocorrected systolic blood pressure an average of -1.3 to -5.3 mmHg from baseline in all of the monotherapy and placebo-controlled add-on combination therapy studies.

Bone Mineral Density and Body Composition in Type 2 Diabetic Patients

A 24-week study (n=182) found a greater reduction in total body weight from baseline to Week 24 in patients taking dapagliflozin 10 mg plus metformin (-2.96 kg), versus placebo plus metformin (-0.88 kg), with a significant interaction for gender [greater weight loss for males

(-2.76 kg) than females (-1.22 kg)]. The reduction in total body fat mass from baseline to Week 24 was -2.22 kg for dapagliflozin and -0.74 kg for placebo with a reduction in percentage total body fat mass from baseline to Week 24 in the dapagliflozin group of 1%, whereas there was little change in the placebo group, as evaluated by dual energy x-ray absorptiometry (DXA).

In an extension of this study to week 102 there was no change in bone mineral density for the lumbar spine, femoral neck, or total hip seen in either treatment group (mean decrease from baseline for all anatomical regions <0.5%).

14.3 Comparative Bioavailability Studies

A randomized, two-treatment, two-sequence, two-period crossover bioequivalence study was performed in 32 healthy, adult, Asian male subjects under fasting conditions. The rate and extent of absorption of dapagliflozin was measured and compared following a single oral dose of M-DAPAGLIFLOZIN 10 mg tablets (Mantra Pharma Inc.) versus FORXIGA® 10 mg tablets (AstraZeneca Canada Inc.). The results from 31 subjects that completed the study are summarized in Table 20.

Dapagliflozin (1 x 10 mg) From measured data Geometric Mean Arithmetic Mean (CV %)					
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90% Confidence Interval	
AUC _T (ng.h/mL)	664.6 673.1 (15.6)	650.9 658.2 (14.9)	102.2	100.3 - 104.1	
AUC _I (ng.h/mL)	707.2 716.2 (15.5)	690.2 697.8 (14.7)	102.5	100.7 – 104.4	
C _{max} (ng/mL)	140.1 152.9 (47.4)	125.0 132.9 (38.8)	112.3	101.8 - 124.0	
T _{max} ³ (h)	1.17 (0.33 – 2.33)	1.67 (0.67 – 3.00)			
T½ ⁴ (h)	6.03 (27.3)	6.10 (23.5)			

¹ M-DAPAGLIFLOZIN (dapagliflozin) tablets, 10 mg (Mantra Pharma Inc.)

² FORXIGA® (dapagliflozin as dapagliflozin propanediol monohydrate) tablets, 10 mg of AstraZeneca Canada Inc.

³ Expressed as the median (range) only

⁴ Expressed as the arithmetic mean (CV%) only

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology

Acute and repeat-dose toxicity: Dapagliflozin demonstrated low acute toxicity. The minimum lethal doses of dapagliflozin following single oral administration were 750 mg/kg in rats and 3000 mg/kg in mice.

Dapagliflozin was well tolerated when given orally to rats for up to 6 months at doses of ≤25 mg/kg/day (up to 340× the human exposures (AUC) at the maximum recommended human dose (MRHD) of 10 mg/day resulting in AUC 0.465 mcg.h/mL, and in dogs for up to 12 months at doses of ≤120 mg/kg/day (up to 3300× the MRHD). In rats, renal lesions (mainly cortical tubular dilatation, medullary tubular dilatation, degeneration, necrosis, mineralization, reactive hyperplasia, and exacerbation of chronic progressive nephropathy), increased trabecular bone, and tissue mineralization (associated with increased serum calcium), were observed at high-exposure multiples (≥2100× the MRHD). Despite achieving exposure multiples of ≥3200× the human exposure at the MRHD, there was no dose-limiting or target organ toxicities identified in the 12-month dog study.

Carcinogenicity

Dapagliflozin did not induce tumors in either mice or rats at any of the doses evaluated in twoyear carcinogenicity studies. Oral doses in mice consisted of 5, 15, and 40 mg/kg/day in males and 2, 10, and 20 mg/kg/day in females, and oral doses in rats were 0.5, 2, and 10 mg/kg/day for both males and females. The highest doses evaluated in mice were equivalent to AUC exposure multiples of approximately 72× (males) and 105× (females) the human AUC at the MRHD. In rats, AUC exposures were approximately 131× (males) and 186× (females) the human AUC at the MRHD. In a 6-month bladder tumour initiation-promotion study in rats with dapagliflozin (7 times MRHD), the results showed that dapagliflozin does not act as promoter or progressor of bladder cancer.

Genetoxicity

Dapagliflozin was negative in the Ames mutagenicity assay, and was positive in *in vitro* clastogenicity assays but only in the presence of S9 activation and at concentrations ≥100 mcg/mL. Dapagliflozin was negative for clastogenicity *in vivo* in a series of studies evaluating micronuclei or DNA repair in rats at exposure multiples >2100× the human exposure at the MRHD. These studies, along with the absence of tumor findings in the rat and mouse carcinogenicity studies, support that dapagliflozin does not represent a genotoxic risk to humans.

Reproductive and Developmental Toxicology

In a study of fertility and early embryonic development in rats, dapagliflozin had no effects on mating, fertility, or early embryonic development in treated males or females at exposure

multiples up to 998× and 1708× the MHRD in males and females, respectively.

In a pre- and postnatal development study, maternal rats were dosed from gestation day (GD) 6 through lactation day 21 at 1, 15, or 75 mg/kg/day, and pups were indirectly exposed *in utero* and throughout lactation. Increased incidence or severity of renal pelvic dilatation was observed in adult offspring of treated dams, at 75 mg/kg/day (maternal and pup dapagliflozin exposures were 1415× and 137×, respectively, the human values at the MHRD). Dose-related reductions in pup body weights were observed at doses ≥15 mg/kg/day (pup exposures were ≥29× the human values at the MRHD). Maternal toxicity was evident only at 75 mg/kg/day, and limited to transient reductions in body weight and food consumption at dose initiation. The no-adverse-effect level (NOAEL) for developmental toxicity was 1 mg/kg/day (maternal exposure was 19× the human value at the MRHD).

In embryo-fetal development studies in rats and rabbits, dapagliflozin was administered for intervals coinciding with the major periods of organogenesis in each species. Neither maternal nor developmental toxicities were observed in rabbits up to the highest dose of 180 mg/kg/day (184× the MRHD). In rats, dapagliflozin was not teratogenic at doses up to 75 mg/kg/day (1441× the MRHD). Doses ≥150 mg/kg/day (≥2344× the MRHD) were associated with both maternal and developmental toxicities.

Developmental toxicity consisted of reduced fetal body weights, increased embryo-fetal lethality, and increased incidences of fetal malformations and skeletal variations. Malformations included great vessel malformations, fused ribs and vertebral centras, and duplicated manubria and sternal centra. Variations were primarily reduced ossifications.

Juvenile Toxicity

In a juvenile toxicity study, when dapagliflozin was dosed directly to young rats from postnatal day (PND) 21 until PND 90 at doses of 1, 15, or 75 mg/kg/day, increased kidney weights and renal pelvic and tubular dilatations were reported at all dose levels; pup exposures at the lowest dose tested were \geq 15× the MRHD. The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within the approximate 1-month recovery period.

17 SUPPORTING PRODUCT MONOGRAPHS

1. FORXIGA[®] Tablets, 5 mg and 10 mg, submission control 248367, Product Monograph, AstraZeneca Canada Inc. (August 6, 2021)

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

^{Pr}M-DAPAGLIFLOZIN

Dapagliflozin tablets

Read this carefully before you start taking **M-DAPAGLIFLOZIN** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **M-DAPAGLIFLOZIN**.

Serious Warnings and Precautions

- Diabetic ketoacidosis (DKA) can happen while you are taking M-DAPAGLIFLOZIN. It is a serious and life-threatening condition, which may need urgent hospital care. Some cases of DKA have led to death. DKA can happen to diabetic patients with normal or high blood sugar levels. In DKA your body produces high levels of blood acids called ketones. It occurs because your body does not have enough insulin.
- Seek medical help right away and stop taking M-DAPAGLIFLOZIN immediately if you have any of the DKA symptoms. Do this even if your blood sugar levels are normal. The symptoms of DKA are: difficulty breathing, nausea, vomiting, stomach pain, and loss of appetite. Confusion, feeling thirsty, feeling unusually tired or sleepy, along with a sweet or metallic taste in the mouth or sweet smelling breath can be noticed. You may have a different odour to your urine or sweat.
- Do not use M-DAPAGLIFLOZIN if you have:
 - DKA or a history of DKA
 - Type 1 diabetes

What is M-DAPAGLIFLOZIN used for?

- M-DAPAGLIFLOZIN is used along with diet and exercise to:
 - improve blood sugar levels in adults with type 2 diabetes. M-DAPAGLIFLOZIN can be used:
 - alone, if you cannot take metformin
 - with metformin
 - with a sulfonylurea
 - with metformin and a sulfonylurea
 - with sitagliptin (with or without metformin)
 - with insulin (with or without metformin)

How does M-DAPAGLIFLOZIN work?

M-DAPAGLIFLOZIN belongs to a class of medicines called Sodium-glucose co-transporter 2 (SGLT2) inhibitors. It removes excess sugar from the body through the urine. This reduces the amount of sugar in the blood.

What are the ingredients in M-DAPAGLIFLOZIN?

Medicinal ingredient: Dapagliflozin.

Non-medicinal ingredients: Anhydrous lactose, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, iron oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, partially hydrolyzed polyvinyl alcohol, polyethylene glycol, talc and titanium dioxide.

M-DAPAGLIFLOZIN comes in the following dosage forms:

Tablets: 5 mg and 10 mg.

Do not use M-DAPAGLIFLOZIN if:

- you are allergic to dapagliflozin or to any of the other ingredients in M-DAPAGLIFLOZIN.
- you are on dialysis.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take M-DAPAGLIFLOZIN. Talk about any health conditions or problems you may have, including if you:

- have type 1 diabetes (your body does not produce any insulin). M-DAPAGLIFLOZIN should not be used in patients with type 1 diabetes.
- have an increased chance of developing diabetic ketoacidosis (DKA), including if you:
 - are dehydrated or suffer from excessive vomiting, diarrhea, or sweating
 - are on a very low carbohydrate diet
 - have been fasting for a while
 - are eating less, or there is a change in your diet
 - drink a lot of alcohol
 - have/have had problems with your pancreas, including pancreatitis or surgery on your pancreas
 - are hospitalized for major surgery, serious infection or serious medical illness. If you

are going to have a surgery and after your surgery, or if you are hospitalized for a major surgery, a serious infection, or a serious medical illness, your healthcare professional may stop your treatment with M-DAPAGLIFLOZIN. Talk to your healthcare professional about when to stop taking M-DAPAGLIFLOZIN and when to start taking it again.

- have a sudden reduction in your insulin dose
- have a history of DKA.
- are older than 65 years of age
- have or have had any kidney problems
- have received immunosuppressive therapy (treatment that lowers the activity of your immune system) to treat your kidney problems.
- are on dialysis
- have or have had any cases of liver disease
- have low blood pressure
- have or have had heart disease or heart failure
- are taking a medicine to lower your blood pressure, including diuretics, known as water pills. If you take M-DAPAGLIFLOZIN with these medicines, it can increase the risk of dehydration.
- are taking medicines to lower your blood sugar. Tell your healthcare professional about all of the medicines you are taking to control your diabetes.
- have a history of yeast infection of the vagina or penis
- have a history of urinary tract infections
- have Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis, which is an autoimmune disease affecting small blood vessels in the body
- have intolerance to some milk sugars. M-DAPAGLIFLOZIN tablets contain lactose.

Other warnings you should know about:

M-DAPAGLIFLOZIN can cause serious side effects, including:

- **Hypotension** (low blood pressure): This is common in patients with high blood sugar (glucose).
- **Hypoglycemia** (low blood sugar) **in patients with type 2 diabetes**: M-DAPAGLIFLOZIN can cause low blood sugar when used with other antidiabetic medications, including insulin. Your healthcare professional may adjust your dose of insulin or other antidiabetic medicines when taking M-DAPAGLIFLOZIN. This is to help you keep your blood sugar levels within the normal range during your treatment.
- Yeast infection: M-DAPAGLIFLOZIN increases your chance of getting a yeast infection of the

vagina or penis, especially if you have had them in the past.

- Urinary tract infection
- Urosepsis: This is a severe infection that spreads from the urinary tract throughout the body. This condition is serious and may be life-threatening if left untreated. If you experience signs of this condition, stop taking M-DAPAGLIFLOZIN right away and seek immediate medical help.
- Fournier's gangrene: This is a serious infection affecting the soft tissue around the groin. Rare cases of Fournier's gangrene have been reported in patients with type 2 diabetes while taking SGLT2 inhibitors like M-DAPAGLIFLOZIN. This condition is serious and may be life threatening. If you experience signs of this condition, stop taking M-DAPAGLIFLOZIN right away and seek immediate medical help.
- **Kidney problems in patients with type 2 diabetes**: This may happen shortly after you start taking M-DAPAGLIFLOZIN.

See the Serious side effects and what to do about them table, below, for more information on these and other serious side effects.

Driving and using machines: Before doing tasks that require special attention, wait until you know how you respond to M-DAPAGLIFLOZIN. Dizziness, light-headedness, or fainting can occur, particularly when M-DAPAGLIFLOZIN is taken with insulin or other antidiabetic medicines.

Pregnancy: M-DAPAGLIFLOZIN should **not** be taken during pregnancy. It is not known if M-DAPAGLIFLOZIN will harm your unborn baby. If you discover that you are pregnant while taking M-DAPAGLIFLOZIN, **stop** the medication and contact your healthcare professional **as soon as possible.**

Breastfeeding: M-DAPAGLIFLOZIN should **not** be taken if you are breastfeeding. It is not known if M-DAPAGLIFLOZIN will pass into your breastmilk and harm your baby. Talk to your healthcare professional about ways to feed your baby if you are planning to breastfeed while taking M-DAPAGLIFLOZIN.

Children and adolescents: M-DAPAGLIFLOZIN is not to be used in children and adolescents under 18 years of age.

Check-ups and testing:

• Your healthcare professional may decide to perform tests before taking M-DAPAGLIFLOZIN and/or during treatment. These tests will check:

- The amount of cholesterol (a type of fat) in your blood
- The amount of red blood cells in your body
- The amount of sugar (glucose) in your blood
- That your kidneys are working properly
- The volume of blood in your body
- The level of electrolytes in your blood

Depending on your test results, your healthcare professional may adjust your dose, temporarily stop or discontinue your therapy with M-DAPAGLIFLOZIN.

• M-DAPAGLIFLOZIN will cause your urine to test positive for sugar (glucose).

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with M-DAPAGLIFLOZIN:

- medicines you take for diabetes to lower your blood sugar levels. This includes sulfonylurea medication such as glyburide, gliclazide or glimepiride, or insulin. If you take M-DAPAGLIFLOZIN with any of these medicines, it can increase the risk of low blood sugar. Your healthcare professional will tell you how much of each medicine to take.
- medicines used to lower your blood pressure, including diuretics, known as water pills. If you take M-DAPAGLIFLOZIN with these medicines, it can increase the risk of dehydration.

How to take M-DAPAGLIFLOZIN:

- as directed by your healthcare professional
- once a day
- at any time of the day
- by mouth
- with or without food

Swallow tablet whole. Do not split, crush or chew M-DAPAGLIFLOZIN tablets.

Usual dose:

The dose of M-DAPAGLIFLOZIN prescribed to you will depend on your condition and your response to treatment.

Patients with type 2 diabetes

To control your blood sugar: the usual adult starting dose is one 5 mg tablet a day. Your healthcare professional may increase your dose to one 10 mg tablet a day, if needed.

Overdose:

If you think you, or a person you are caring for, have taken too much M-DAPAGLIFLOZIN, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose of M-DAPAGLIFLOZIN, take it as soon as you remember. If you do not remember until it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose.

What are possible side effects from using M-DAPAGLIFLOZIN?

These are not all the possible side effects you may feel when taking M-DAPAGLIFLOZIN. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- sore throat
- flu (fever, tiredness, body aches)
- stuffy or runny nose
- constipation
- diarrhea
- nausea
- back pain
- pain in the arms, legs, hands or feet
- headache
- rash
- joint pain

If any of these affects you severely, tell your healthcare professional.

M-DAPAGLIFLOZIN can cause abnormal blood test results. Your healthcare professional will decide when to perform blood tests. They will tell you if your test results are abnormal and if you need treatment to correct these side effects.

Serious side effects and what to do about them				
	Talk to your healt	hcare professional	Stop taking drug	
Symptom / effect	Only if severe	In all cases	and get immediate medical help	
COMMON				
Urinary tract infection: Pain or burning sensation while urinating, frequent urination, blood in urine, pain in the pelvis, strong smelling urine, cloudy urine		\checkmark		
Yeast infection of vagina: severe itching, burning, soreness, irritation, and a whitish or whitish-gray cottage cheese-like discharge	\checkmark			
Yeast infection of penis: red, swollen, itchy head of penis, thick, lumpy discharge under foreskin, unpleasant odour, difficulty retracting foreskin, pain passing urine or during sex	\checkmark			
UNCOMMON				
Volume depletion (loss of needed fluids from the body; dehydration): dry or sticky mouth, headache, dizziness or urinating less often than normal, thirst		\checkmark		
Hypotension (low blood pressure): dizziness, fainting, lightheaded-ness; may occur when you go from lying to sitting to standing up		√		
Hypoglycemia (low blood sugar) in patients with type 2 diabetes: shaking, sweating, rapid heartbeat, change in vision, hunger, headache and change in		\checkmark		

Serious side effects and what to do about them				
	Talk to your healt	hcare professional	Stop taking drug	
Symptom / effect	Only if severe	In all cases	and get immediate medical help	
mood				
RARE				
Diabetic ketoacidosis (DKA) in patients with type 2 diabetes: difficulty breathing, nausea, vomiting, stomach pain, loss of appetite, confusion, feeling very thirsty, feeling unusual tiredness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat			\checkmark	
Kidney problems in patients with type 2 diabetes: any change in the amount, frequency or colour (pale or dark) of urine		\checkmark		
Fournier's gangrene (a serious infection affecting soft tissue around the groin): pain or tenderness, redness of the skin, or swelling in the genital or perineal area, with or without fever or feeling very weak, tired, or uncomfortable			\checkmark	
VERY RARE				
Acute kidney infection: painful, urgent or frequent urination, lower back (flank) pain, fever or chills, cloudy or foul smelling urine, blood in your urine			\checkmark	
Urosepsis (severe infection that spreads from urinary tract throughout body): fever or low body temperature, chills, rapid			\checkmark	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug
	Only if severe	In all cases	and get immediate medical help
breathing, rapid heartbeat, pain with urination, difficulty urinating, frequent urination			
Pancreatitis (inflammation of the pancreas): upper abdominal pain, fever, rapid heart beat, nausea, vomiting, tenderness when touching the abdomen		\checkmark	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-healthproducts/medeffect-canada.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature (15 to 30 °C).

Keep M-DAPAGLIFLOZIN out of the reach and sight of children.

If you want more information about M-DAPAGLIFLOZIN:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website

(https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); or by contacting Mantra Pharma Inc. at medinfo@mantrapharma.ca or at 1-833-248-7326.

This leaflet was prepared by Mantra Pharma Inc. 9150 Leduc Blvd., Suite 201 Brossard, Quebec J4Y 0E3

Last Authorized: FEB 08, 2023